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INTRODUCTION 
 
Urinary tract infection is the most common infection affecting patients 
with type 2 diabetes mellitus.[59] It is defined as an infection of the urinary 
bladder, urethra, kidneys, renal pelves, or ureters.[86] Urinary tract infection is a 
common cause of morbidity in patients suffering from Diabetes 
mellitus.[1]Diabetic individuals are at higher risk of developing urinary tract 
infections. In an autopsy study done in 1940, it was seen that about 18% of 
diabetic subjects had urinary tract infection.[13]Diabetes mellitus is diagnosed 
when a patient shows a plasma glucose 126mg/dl in the fasting state or 2 hour 
post prandial plasma glucose 200mg/dl.[10] 
 
Diabetic individuals are more prone for infections than other individuals 
due to several factors including immunological dysfunctions of 
polymorphonuclear leukocytes like impaired migration, intracellular killing, 
phagocytosis, and chemotaxis. The risk of urinary tract infection in diabetic 
patients is further enhanced by local complications including neuropathy leading 
to impaired bladder emptying and nephropathy.[71] 
 
Urinary tract infections may be symptomatic or asymptomatic. Many 
UTIs are asymptomatic, and whether symptomatic UTIs are preceded by 
asymptomatic bacteriuria (ASB) is not known.[13] Asymptomatic bacteriuria or 
asymptomatic UTI is the isolation of a specified quantitative count of bacteria in 
an appropriately collected urine specimen obtained from a person without 
symptoms or signs of urinary infection.[85] In asymptomatic women, bacterial 
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count less than 105 bacteria/mL represents contamination. In asymptomatic men, 
103 or more organisms/mL in one culture is suggestive of infection as the 
contamination is less expected.[85] Pure growth of Enterobacteriaceae is found in 
over 90% of urine samples containing more than 105 bacteria/mL. Gram-positive 
organisms, fungi, and fastidious bacteria may grow at titres less than 105/mL in 
patients with infection and may be in the 104 to 105/mL range. Presence of more 
than one species of bacteria in high colony counts in asymptomatic patients may 
represent contamination while it is significant in symptomatic individuals. 
Mixed infection occurs in about 5% of cases of urinary tract infection. 
 
The medulla of the kidney contains hypotonic urine which provides an 
unfavourable environment for growth of microorganisms. This is disrupted in 
diabetic individuals due to the high osmolarity produced by the glucose in 
urine.[85] 
 
From Microbiological perspective, urinary tract infection exists when 
pathogenic microorganisms are detected in urine in significant numbers, urethra, 
bladder, kidney or prostate. In most instances, growth of >105 organisms per 
milliliter from a properly collected midstream clean catch urine samples 
indicates infection.[11]  
 
Significant bacteriuria refers to the growth of bacteria in voided urine in 
numbers exceeding that found by contamination from the anterior urethra (>105 
organisms per ml).[84] 
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Among the organisms producing urinary tract infections, Gram negative 
bacteria were the most frequently isolated, out of which Escherichia coli was the 
most common.[1] followed by Klebsiella pneumoniae, Proteus spp. The Gram 
positive bacteria producing urinary tract infections commonly, includes 
Staphylococcus aureus, Enterococcus spp., Staphylococcus saprophyticus and 
Staphylococcus epidermidis. 
 
Antibiotic resistance has been designated as a global health problem. 
Gram negative organisms show several mechanisms of antibiotic resistance 
leading to the emergence of multi drug resistant and pan drug resistant 
organisms.[64] The most common mechanisms of antibiotic resistance seen in 
gram negative bacteria include extended spectrum beta lactamase(ESBL), Amp 
C beta lactamase and metallo beta lactamase production.  Escherichia coli and 
Klebsiella pneumoniae show an increased frequency of expression of ESBLs and 
Amp C expression. Klebsiella pneumoniae and Pseudomonas has been reported 
to produce metallo betalactamases frequently. 
 
An increased incidence of antibiotic resistance mechanisms like extended 
spectrum betalactamase (ESBL), Amp C and metallobetalactamase producing 
strains among Gram negative bacterial isolates has resulted in a limitation of 
therapeutic alternatives, causing treatment failures and are increasing in 
occurrence worldwide [6][4].  
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AIMS AND OBJECTIVES 
 
1. To determine the prevalence of urinary tract infection in patients with type 
2 Diabetes mellitus 
2. To identify the various bacteria producing urinary tract infection in 
patients with Type 2 Diabetes mellitus 
3. To identify the antibiotic sensitivity pattern in the organisms isolated 
4. To detect ESBL, Amp C and metallo betalactamase production among the 
identified organisms by phenotypic screening and confirmatory tests. 
5. To detect the specific genes encoding ESBL, Amp C and MBL production 
in the resistant organisms isolated. 
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REVIEW OF LITERATURE 
 
Patients with diabetes mellitus are more prone to develop infections with 
urinary tract infection being the most common amongst all infections in diabetic 
patients.[13] Urinary tract infections can produce cases of gram negative sepsis in 
hospitals especially in catheterised patients. [85] 
 
EPIDEMIOLOGY 
In the global scenario, more than 400 million adults live with diabetes.[92] 
India has been estimated to have the largest number of diabetic patients in the 
world. About 40.9 million individuals are affected with diabetes mellitus in 
India.[14] In South India the prevalence of urinary tract infection in diabetic 
patients is 42%.[8] The frequency of urinary tract infections in diabetic 
individuals are 60% higher than non diabetics.[82] The prevalence of 
asymptomatic bacteriuria was found to be 26% in patients with diabetes as 
opposed to 6% in non diabetics. 
 
Females are more prone for urinary tract infection than males in the age 
group between 1-50 years of age.[11] In post menopausal women, the risk factors 
for urinary tract infection includes Diabetes mellitus, incontinence and sexual 
intercourse. The likelihood of admissions due to Acute pyelonephritis has been 
found to be 6-24 times more in diabetic women and 3.4 - 17 time more in diabetic 
men as compared to their non diabetic counterparts.[72] 
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ETIOLOGICAL AGENTS OF URINARY TRACT INFECTION IN 
DIABETES MELLITUS 
The etiological agents associated with urinary tract infection are classified 
according to the source of infection. 
 
Community Acquired Urinary tract infection 
Escherichia coli is the most common cause of uncomplicated urinary tract 
infection. Among Escherichia coli Uropathogenic Escherichia coli(UPEC) is the 
most common. Other organisms producing uncomplicated urinary tract 
infections include Klebsiella spp., other Enterobacteriaceae, Staphylococcus 
saprophyticus, and Enterococci. 
 
In complicated urinary tract infection like recurrent infections the overall 
frequency of other organisms like Proteus, Pseudomonas, Klebsiella, and 
Enterobacter spp was higher. 
 
Hospital Acquired Urinary Tract Infection 
The spectrum of organisms involved in Hospital Acquired Urinary Tract 
infection depends on the hospital environment. The most common organisms 
associated with hospital acquired urinary tract infection include E. coli, 
Klebsiella spp., Proteus spp., Staphylococci, Pseudomonas aeruginosa, 
Enterococci, and Candida spp. 
Urinary tract infection comprises 35% of all hospital-acquired infections. 
Eighty percent of those infections are associated with the use of an indwelling 
catheter. [85] 
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MISCELLANEOUS 
Other less frequently isolated agents are other gram negative bacilli, such 
as Acinetobacter and Alcaligenes spp., Citrobacter spp., Gardnerella vaginalis, 
Aerococcus urinae, and beta-hemolytic streptococci. 
 
PATHOGENESIS OF URINARY TRACT INFECTIONS IN DIABETES 
MELLITUS 
Diabetic patients are more prone for infections which maybe due to the 
immunological changes which occur.  
 
HOST FACTORS  
In patients with diabetes mellitus the innate immune system is affected 
more than the acquired immune system. Defective neutrophil chemotaxis, 
neutrophil adherence to vascular endothelium, phagocytosis, intracellular 
bactericidal activity and opsonisation are seen in patients with uncontrolled 
diabetes mellitus. Cytokines show a normal concentration in the blood but the 
response to stimuli is reduced in patients with diabetes mellitus. 
 
Hyperglycemia leads to impairment of opsonophagocytosis by diverting 
nicotinic acid adenine dinucleotide phosphate (NADPH) from superoxide 
production to aldose reductase dependent polyol pathway leading to further 
impairment of phagocytosis.[90][91][89] 
 
Other host related factors which predispose to infection in diabetic 
individuals include vascular insufficiency (microangiopathies and 
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macroangiopathies), sensory peripheral neuropathy and autonomic 
neuropathy.[90][91][89] Urinary stasis and retention are common in diabetic patients 
with autonomic neuropathy due to loss of innervation of the bladder.[90][91][89] 
 
Colonisation of the vaginal or periurethral region with organisms from 
the gastrointestinal tract is a common occurrence especially in women. The 
postmenopausal women are more prone for cystitis due to vaginal E.coli 
colonisation. The greater adherence of Type 1 fimbriated E.coli to uroepithelial 
cells in women with diabetes maybe due to the impaired cytokine secretion as 
wells as neutrophil response.[90][91][89] The probability of an organism causing a 
urinary tract infection is largely dependant on a complex interplay of host and 
microbial factors. [85] The urinary tract does not harbour any bacteria except in 
the urethra that is colonised with commensal micro organisms.Urine has an 
inhibitory effect on certain organisms like anaerobes.[85] 
 
Commensal Microbiota found in the urethra includes 
 α/α-Hemolytic streptococci 
 Bacillus spp. 
 Coagulase-negative staphylococci 
 Diphtheroids 
 Lactobacillus spp. 
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There are three possible routes of infection for UTI: 
1. Ascending, 
2. Hematogenous, and  
3. Lymphatic pathways[84] 
 
ASCENDING ROUTE 
The urethra is usually colonised by bacteria. The spread of infection 
occurs from the urethra towards bladder. Here the organisms multiply and reach 
the upper urinary tract including the renal pelvis and parenchyma.  
 
Urinary tract infection is more common in women as compared to men 
probably due to ascending route of infection. The short female urethra along with 
the proximity to the vulvar and perianal regions favours this route of infection. 
 
HEMATOGENOUS ROUTE 
Infection of the renal parenchyma by bloodborne organisms occur 
through this route of infection. It is more common with Staphylococcus aureus 
bacteremia or endocarditis, or both. However, Gram negative bacilli which are 
the most common organisms producing urinary tract infections very rarely 
produce infection through this route. 
 
LYMPHATIC ROUTE 
This is very rare route of infection. This is based on the hypothesis that 
increased pressure in the lymphatics of bladder causes increased flow to the 
kidney. 
10 
 
Risk Factors for Complicated Urinary Tract Infections include 
 Underlying diseases(e.g., diabetes, sickle cell anemia) 
 Kidney stones 
 Abnormalities of the urinary tract with respect to structure and function. 
 Indwelling urinary catheters 
 
ANTIBACTERIAL HOST DEFENSES IN THE URINARY TRACT 
 Urine (osmolality, pH, organic acids) 
 Urine flow and micturition 
 Urinary tract mucosa (bactericidal activity, peptides, cytokines)— Innate 
immunity 
Inflammatory response 
 Polymorphonuclear neutrophils (PMNs) 
 Tamm-Horsfall protein 
 Cytokines 
Low-molecular-weight oligosaccharides 
 Secretory immunoglobulin A (SIgA) 
 Lactoferrin 
 Peptides 
Adaptive immune system 
 Humoral immunity 
 Cell-mediated immunity 
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Miscellaneous 
 Prostatic secretions[86] 
 
The most common organism associated with urinary tract infection in 
diabetes mellitus is Escherichia coli especially the uropathogenic E.coli. 
Klebsiella spp. is also a common agent causing UTI in diabetic patients 
especially the severe forms like emphysematous pyelonephritis. Other organisms 
producing UTI in diabetic patients include Acinetobacter species, Group B 
streptococcus and Pseudomonas aeruginosa. 
 
Pseudomonas aeruginosa is more common in individuals who have been 
hospitalised or undergone recent instrumentation. 
Specific serogroups of Escherichia coli are associated with urinary tract 
infection known as Uropathogenic Escherichia coli or (UPEC) which contain 
virulence factors which aid in colonisation and invasion of the urinary tract. 
 
Probable Virulence Factors of Uropathogenic E. coli include:-[21] 
Type 1 fimbriae that bind to uroepithelial cells 
Type P fimbriae that recognize kidney glycosphingolipids 
Siderophores that help gather iron from the host 
Alpha and beta hemolysins that lyse host erythrocytes 
Capsules 
Sat protein that acts as a proteolytic toxin[85] 
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Adherence has been demonstrated as an important virulence factor for 
other bacteria like Proteus species also. Proteus also produces urease which 
hydrolyses urea, thus increasing the pH of urine leading to damage to kidney 
tissues as well as formation of calculi in urine. Staphylococcus saprophyticus 
also adheres better to uroepithelial cells better than S. aureus or S. epidermidis. 
 
Protection from host defences like phagocytosis by the presence of the 
capsular antigen (K antigen) plays an important role in the survival of these 
organisms in urine. The motility of the organism is an important determinant of 
whether the organism can produce an upper urinary tract infection as they aid in 
movement against the flow of urine. 
 
In some cases, there is the occurrence of recurrent urinary tract infections. 
This occurs in spite of the host defence mechanisms and antibiotic treatment. 
This is due to the persistence of Escherichia coli by invading and replicating in 
the superficial epithelial cells of the bladder. The host immune response is 
triggered due to this epithelial cell invasion leading to exfoliation of these cells 
within hours of infection. This allows the organisms to reemerge from these cells 
and reinfect the new superficial layer of epithelial cells leading to recurrence and 
persistence of infection. Intracellular bacteria may mature into numerous large 
projections known as “pods” in which intracellular bacteria get embedded in a 
fibrous polysachharide rich matrix resembling a biofilm. [85] 
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CLINICAL MANIFESTATIONS OF URINARY TRACT INFECTION 
Urinary tract infection may be classified based on the site of infection as 
urethritis, ureteritis, cystitis, the urethral syndrome, and pyelonephritis.  
Urethritis 
It is associated with lower urinary tract symptoms like frequency of 
urination and dysuria. It is most commonly produced by Chlamydia trachomatis, 
Neisseria gonorrhoeae, and Trichomonas vaginalis which are sexually 
transmitted infections.[85] 
Ureteritis 
Infection in the ureters is considered along with kidney infections as this 
indicated the ascending pattern of infection. 
Cystitis 
The patients suffering from cystitis typically complain of dysuria, 
frequency and urgency of urination. Other symptoms of cystitis include 
hesitancy, hematuria and suprapubic discomfort. This occurs due to the 
inflammation of the bladder as well as multiplication of bacteria in the urine and 
urethra. Macroscopically, the urine may be cloudy with bad odour and in some 
cases bloody. The infection being present in a localised region does not produce 
fever and systemic symptoms.[85] 
Acute Urethral Syndrome 
Young, sexually active women are the most common patients who present 
with dysuria, frequency, and urgency but yield fewer organisms than 105 colony-
forming units of bacteria per milliliter (CFU/mL) urine on culture. 
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The organisms associated with this syndrome are usually associated with 
cystitis but the number of organisms are less than 105 CFU/mL of urine. Here a 
cut off of 102 CFU/mL is preferred associated with pyuria. The number of pus 
cells should be more than or equal to 8 or more leukocytes per cubic millimetre 
on microscopic examination of uncentrifuged urine.[85] 
Pyelonephritis 
Inflammation of the kidney parenchyma, calices and pelvis is referred to 
as pyelonephritis. This is generally of bacterial etiology. Fever and flank pain 
frequently along with lower tract symptoms (frequency, urgency, and dysuria) 
are the common manifestations of pyelonephritis. They can also develop 
systemic features like as vomiting, diarrhoea, chills, increased heart rate, and 
lower abdominal pain. 
Urosepsis 
Urosepsis constitutes about 25% of the cases in sepsis. Early diagnosis 
and treatment of urinary tract infections are essential in preventing urosepsis. 
 
Asymptomatic bacteriuria 
Asymptomatic bacteriuria is defined as the isolation of specific 
quantitative counts of bacteria in a urine sample from an individual who has no 
symptoms of urinary tract infection. [85] 
Screening and treatment for asymptomatic bacteriuria is recommended 
for pregnant women, males undergoing transurethral resection of the prostate, 
and individuals undergoing urologic procedures for which mucosal bleeding is 
anticipated. 
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LAB DIAGNOSIS OF URINARY TRACT INFECTION 
SAMPLE COLLECTION 
Urine samples need to be collected with special precautions to avoid 
contamination of the sample by bacteria from the vaginal canal, the perineum, or 
indigenous bacterial microbiota in the urethra[86] 
 
The types of samples that can be collected for urine includes:- 
1. Midstream clean catch urine sample 
2. Supra pubic aspiration 
3. Catheterised patients 
 
MID STREAM CLEAN CATCH URINE SAMPLE COLLECTION 
COLLECTION IN FEMALE PATIENTS 
Gauze pads saturated with soapy water is used to clean the periurethral 
and perineal region with a front to back motion. The area is then rinsed with 
sterile water or saline. The labia is held apart and first few milliliters of urine 
passed into a bedpan or toilet bowl to remove bacteria from the urethra. The urine 
is collected in a sterile, wide-mouthed container that can be covered with a 
tightly fitted lid. Urine transport tubes with preservatives may be used when a 
delay is expected between collection of sample and culture.  
The accuracy of urine sample collection can be assessed by monitoring 
the number of specimens showing colony counts between 10,000 to 100,000 
CFU/ml.The number of samples showing such intermediate counts should be 
less than 10%. 
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COLLECTION OF URINE SAMPLE IN MALE PATIENTS 
The urethral meatus should be cleansed with soap and water before 
voiding. The mid stream sample is collected by discarding initial few ml of urine 
and collecting the urine into sterile, wide mouthed containers with lids. 
 
COLLECTION OF URINE SAMPLE FROM INCONTINENT ELDERLY 
MALE PATIENTS  
The glans penis is cleaned with soap and water and rinsed with saline. 
The leg bag is examined every 10-15 minutes and once the sample is collected it 
is transferred to culture media immediately due to risk of overgrowth of 
contaminant organisms. 
In the case of urethritis, the initial voided urine sample is of significance. 
For the isolation of fastidious organisms like Neisseria gonorrhoeae or 
Chlamydia trachomatis urethral swabs inserted to the distal urethra may be 
used.[86] 
 
CATHETER COLLECTION 
Using catheter for the sole purpose of obtaining a urine sample for culture 
is not recommended. Catheterization with strict aseptic technique is used for 
sample collection only in patients who are unable to produce an adequate 
midstream sample. The initial few ml of sample is discarded to avoid the growth 
of contaminant organisms from the catheter tip during insertion.[86] 
Indwelling catheters are not good sources of sample due to the difficulty 
in differentiating between colonisers and pathogens. 
17 
 
SUPRA PUBIC ASPIRATION 
This method is used almost exclusively for neonates and small children. 
It is done on a full bladder. The suprapubic skin overlying the bladder is 
disinfected and sterile drapes are put in place.1% Lidocaine is injected 
subcutaneously at the site of aspiration. An 18-gauge, short-bevel spinal needle 
is inserted into the urinary bladder and 10 mL of urine is aspirated into the 
syringe.[86] 
 
SPECIMEN TRANSPORT 
The processing of a urine sample should be done ideally within 2 hours 
of collection of sample for accurate results. If a delay is expected in processing 
of the samples, it can be refrigerated or kept in specific preservatives. 
Refrigeration maintains the bacterial counts for upto 24 hours.Urine transport 
tubes from (BD Urine Culture Kit containing boric acid, glycerol, and sodium 
formate preserves bacteria without refrigeration for as long as 24 hours. 
 
PROCESSING OF THE URINE SAMPLE 
MACROSCOPY 
Freshly voided urine is usually clear and pale yellow or yellow depending 
on the concentration[94] Urine sample has to be assessed for the following 
parameters macroscopically: 
1. Colour 
2. Turbidity 
3. Visible Blood 
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Cloudy urine with an unpleasant smell may be indicative of bacterial 
infection. If the urine is red and cloudy it may be due to Schistosomiasis or 
bacterial infection. Brown and cloudy urine may be due to some type of 
intravascular hemolysis or in malaria hemoglobinuria. Yellow brown or green 
brown urine maybe seen in Acute hepatitis and obstructive jaundice due to the 
presence of bilirubin .Urine with a yellow – orange colour indicates presence of 
urobilinogen seen in hepatocellular jaundice and hemolysis. Milky white urine 
also known as Chyluria is seen in Bancroftian filariasis due to presence of Chyle 
in urine. 
 
SCREENING PROCEDURES 
A good screening method helps to reduce the unnecessary use of culture 
media and technologist time. It also provides information about the presence or 
absence of bacteriuria and pyuria on the same day which is helpful for deciding 
empirical therapy by the physician. 
WET FILM EXAMINATION 
A leucocyte count is obtained by wet film examination of uncentrifuged 
urine samples provided the area of microscopy field and the depth of the film is 
known. The wet film is observed under high power (40x). 0.05 ml of urine is 
placed on the centre of the slide and a coverslip is placed immediately to achieve 
a depth of 0.01 mm. The area observed is calculated from the diameter of the 
high power lens measured by a slide micrometer .The finding of 1 leucocyte per 
7 HPF is equivalent to 104 leukocytes per ml. 
 
19 
 
GRAM STAINING OF URINE SAMPLES 
This is a simple, inexpensive method of detecting bacteria and pus cells 
in urine. A drop of well-mixed urine is smeared onto the slide and allowed to air-
dry, the smear is fixed, stained, and examined under oil immersion (1000×) for 
the presence of 1 or 5 bacteria per oil immersion field (OIF).This has a sensitivity 
of 96% and a specificity of 91% when correlated with the significant bacteruria. 
Gram stain is not reliable for the detection of polymorphonuclear leukocytes in 
urine as they deteriorate quickly in urine. 
 
The presence of polymorphonuclear neutrophils(PMNs) can be detected 
and quantified in uncentrifuged urine specimens. The excretion of ≥ 8 
Polymorphonuclear neutrophils/mm3 of urine indicates infection. However, 
pyuria can be associated with other clinical conditions like vaginitis and hence 
is not specific for urinary tract infection. 
 
INDIRECT INDICES 
Indirect indices detect bacterial enzymes or PMN enzymes gives an 
indirect evidence of infection without visualising the PMN or organisms[85] 
 
NITRATE REDUCTASE (GREISS) TEST.  
This test detects the presence of nitrite in urine specimen as an indicator 
of UTI. Most of the organisms producing urinary tract infections produce nitrate 
reducing enzymes which reduce nitrate to nitrite. This is available in a paper strip 
impregnated with the specific reagents. 
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LEUCOCYTE ESTERASE TEST 
Leucocyte esterase is an enzyme produced by the inflammatory cells. The 
detection of leucocyte esterase correlates well with the hemocytometer chamber 
counts of PMNs. The leucocyte esterase test along with nitrate reductase tests 
are both incorporated into a paper strip. 
The sensitivity of detection of in the combined strip is more when 
compared to individual tests done alone but it is still not good as a single 
screening test. 
 
CATALASE 
This is a rapid urine screening test based on the detection of catalase 
produced by most of the common organisms producing urinary tract infection. 
 
1.5 to 2 mL of urine is added to a tube containing dehydrated substrate. 
Hydrogen peroxide is added to the urine, and the solution is mixed gently. The 
formation of bubbles above the liquid surface indicates a positive test. 
 
CHROMOGENIC MEDIA FOR URINARY TRACT INFECTION 
The first used medium for detecting urinary pathogens by chromogenic 
media included the use of glucuronidase as a substrate for specific identification 
of Escherichia coli which is the most common urinary pathogen. Escherichia 
coli appeared as pink or red color colonies. Later this media was modified to 
include glucosidase for identification of enterococci as small green colonies and 
the Klebsiella – Enterobacter Serratia group as larger green colonies. The 
addition of tryptophan and iron salts to this media allowed identification of 
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Proteae group of organisms which formed brown colonies due to deaminase 
activity. 
 
AUTOMATED AND SEMIAUTOMATED SYSTEMS FOR SCREENING OF 
URINE SAMPLES 
iRIcell Systems 
This system analyses both the microscopic and biochemical assays to 
screen for the presence of significant bacteruria. 
 
Sysmex UF-100 
This system identifies cellular structure of leucocytes and bacteria, 
thereby screening urine samples[85] 
 
URINE CULTURE 
INOCULATION OF URINE 
The inoculation of urine onto the specific media is done by semi 
quantitative method 
 
STANDARD LOOP METHOD 
Urine sample is mixed well by gentle rotation. A well mixed urine sample 
is taken in a calibrated loop which delivers a volume of 0.01 or 0.001ml of urine. 
The calibrated loop is inserted vertically into the urine sample in a cup. This 
ensures that the accurate amount of urine is picked up by the loop. [85]The sample 
is inoculated into a Blood agar plate and Mac Conkey agar plate or a Cystine 
Lactose Electrolyte Deficient (CLED) agar plate. 
22 
 
The loop is touched towards the centre of the plate and spread in a line 
across the diameter of the plate. The loop is passed over the line of inoculation 
several times without re-entering the urine or flaming the loop. This technique is 
used to allow the growth of the organisms as isolated colonies which can be 
quantified on the next day.[86] Once inoculated they are incubated for a period of 
24 hours at 35°C. 
 
FILTER PAPER METHOD 
A standard 6mm wide strip of filter paper is bent into L shape with a 12 
mm foot which is sterilised at 160°C for 1 hour. The angulated end and the foot 
are dipped into a sample of uncentrifuged urine and removed. The foot is then 
pressed onto the surface of a well dried agar plate. 8 to 10 samples can be 
inoculated onto a 90 mm agar plate. A maximum of 50 colonies may be 
countable and the others are reported at semiconfluent or confluent. 
 
DIP SLIDE METHOD 
A dipslide consists of a plastic tray with the appropriate media in a 
universal container held on a stalk to the cap of the container. The midstream 
clean catch urine is collected in a universal container, the dipslide is immersed 
in the urine and returned to its universal container. The charged dipslide is 
received at the laboratory and incubated at 37°C overnight and examined for 
growth of colonies. The viable bacteria count is estimated from the number of 
colonies or the pattern of semiconfluent and confluent colonies.  
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Cystine Lactose Electrolyte Deficient (CLED) agar 
This is a medium used widely for the isolation of urinary pathogens as it 
allows the growth of both Gram positive and Gram Negative organisms as well 
as gives consistent results. It is electrolyte deficient and hence inhibits the 
swarming of Proteus spp.[93] 
 
INTERPRETATION OF URINE CULTURE 
REPORTING BACTERIAL NUMBERS 
The number of bacteria or colony forming units (CFU) are estimated by 
multiplying the number of bacterial colonies isolated by the calibration of the 
loop used. Bacterial counts less than 10,000 organisms /ml is considered as not 
significant, counts between 10,000 to 1,00,000 organisms/ ml is of doubtful 
significance (confirmed by a repeat culture) and more than 1,00,000 
organisms/ml is taken as a significant bacteriuria.  
 
ANTIMICROBIAL SUSCEPTIBILITY TESTING[86] 
INOCULUM PREPARATION 
Inoculum is prepared from a broth suspension of the organism incubated 
for 4-6 hours so that the bacteria are in the logarithmic phase. The turbidity of 
the suspension is adjusted to approximately 108 colony-forming units (CFUs) per 
milliliter by comparing its turbidity to a McFarland 0.5 BaSO4 standard. 
 
SUSCEPTIBILITY TESTING 
Antimicrobial susceptibility testing is done by Kirby Bauer disk diffusion 
method. The principle of the test involves the diffusion of the drug from the 
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impregnated disc through the agar. The disks are 6mm wide with a known drug 
concentration kept at a distance of 24mm from each other measured from the 
centre of each disk. When the antimicrobial agent impregnated disc comes into 
contact with the moist agar surface, the water is absorbed by the filter paper and 
the drug diffuses into the medium. The concentration of the drug closest to the 
disc is maximum and there is a logarithmic decrease in the concentration of the 
drug while moving away from the disc. The bacteria start growing once the 
critical cell mass of bacteria overcome the drug concentration. These points of 
attaining the critical cell mass is demonstrated as a zone of inhibition. 
 
COMPLICATIONS OF URINARY TRACT INFECTION IN DIABETIC 
PATIENTS [85] 
The various complications associated with diabetic urinary tract infection 
include: 
1. Emphysematous Pyelonephritis 
2. Renal and Perinephric abscess 
3. Renal papillary necrosis 
4. Prostatic Abscess[81] 
 
MANAGEMENT OF URINARY TRACT INFECTION IN DIABETES 
PATIENTS 
Treatment of urinary tract is based on the type of infection as well as the 
population infected. 
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1. Uncomplicated cystitis in women 
a) Trimethoprim-sulfamethoxazole (TMP-SMX) at a dosage of 1 DS tablet 
BD for 3 days is recommended as first line agent except in places with 
reported resistance more than 20%. 
b) Nitrofurantoin at a dosage of 100mg BD for 5-7 days is another first line 
agent preferred for acute cystitis 
c) Flouroquinolones are given only when other antibiotics cannot be given 
owing to the emergence of resistance and the development of antibiotic 
associated diarrhoea. 
2. Pyelonephritis 
a) Fluoroquinolones (Ciprofloxacin 500mg P.O BD for 7 days) is preferred 
for uncomplicated pyelonephritis 
b) Oral Trimethoprim-sulfamethoxazole (TMP-SMX) at a dosage of 1 DS 
tablet BD for 14 days is useful if the organism is susceptible. 
3. Urinary tract infection in men 
7-14 days course of Fluoroquinolones or Trimethoprim-sulfamethoxazole 
is effective 
4. Prostatitis 
Antibiotics are prescribed after the urine and blood are collected for 
culture. Treatment is given as per the culture results and continued for 2-4 weeks. 
5. Catheter associated urinary tract infection 
The catheter should be replaced and appropriate antibiotic treatment 
initiated as per the culture and antibiotic susceptibility results.  
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BACTERIAL RESISTANCE 
The discovery of Penicillin from Penicillium notatum by Alexander 
Fleming in 1928 was one of the greatest discoveries of the 20th century.[86]The 
development of resistance in the bacteria against the antibiotics started growing 
with the injudicious use of antibiotics in the human and veterinary practice. 
Antibiotic susceptibility testing became a clinical necessity for the prescription 
of effective drugs. 
 
The antibiotic resistance may be of 2 types:- 
1. Natural resistance:- 
The organisms lack the target site or the metabolic pathway that the drug 
targets. 
 
2. Acquired resistance:- 
Development of antimicrobial resistance due to the excessive use of the 
antimicrobial for long duration is termed as acquired reisistance. This is 
developed by either mutation or gene transfer. 
 
Four major targets for the action of antibiotics are present 
1. Inhibition of cell wall biosynthesis 
a) Penicillins, 
b) Cephalosporins, 
c) Cycloserine, 
d) Vancomycin, 
e) Bacitracin.  
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2. Leakage from cell membranes: 
a) Polymyxins, 
b) Colistin, 
c) Bacitracin.  
3. Inhibition of protein synthesis 
a) Tetracyclines, 
b) Chloramphenicol,  
c) Erythromycin, 
d) Clindamycin, 
e) Linezolid. 
4. Misreading of mRNA code and affects permeability 
Aminoglycosides- Streptomycin,Gentamicin 
5. Inhibit DNA gyrase: 
Fluoroquinolones—Ciprofloxacin and others. 
6. Interfere with DNA function: Rifampin. 
7. Interfere with intermediary metabolism: 
a) Sulfonamides,  
b) Sulfones, 
c) PAS,  
d) Trimethoprim, 
e) Metronidazole.[94] 
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RESISTANCE TO β-LACTAM ANTIBIOTICS 
The main mechanisms of resistance to β-lactam antibiotics can be due to  
1. Destruction or modification of antibiotic by β-lactamase,  
2. Blocking of penetration accross the outer membrane of gram-negative  
bacteria to reach PBP targets, 
3. efflux of drug across the outer membrane of gram-negative bacteria, 
4. low-affinity binding of antibiotic to target PBPs[85] 
 
β-Lactamases 
These bacterial enzymes are the most common cause of resistance to 
betalactam antibiotics. The β-Lactamases act by cleaving the amide bond in the 
four-atom β-lactam ring structure of penicillins or cephalosporins leading to the 
production of pencillinoic acid and cephalosporic acid,respectively rendering 
them inactive against the bacteria.  
 
In 1944, the first β-Lactamase a Penicillinase which conferred Penicillin 
resistance in Staphylococcus species was discovered. In 1963, TEM-1 was 
discovered in Escherichia coli at Athens followed by SHV-1 in Escherichia coli 
at Switzerland. 
 
In 1988, there was the emergence of metallo betalactamases in 
Pseudomonas aeruginosa in Japan. 
 
In 1989, the inhibitor resistant penicillinases were reported from France, 
Spain and Greece 
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The efficiency of the enzyme depends on its specificity for the betalactam 
antibiotic. Physiologically, the betalactamases helps in restructuring the 
peptidoglycan during cell growth. [86] 
 
Classification of Betalactamases[86] 
Bush 
Jacoby 
(2010) 
Bush 
Jacoby 
(1995) 
Ambler 
Antibiotic 
Substrate 
Inhibited by 
 Representative 
Enzymes CA or 
TZB 
EDTA 
1 1 C Cephalosporins No No 
Amp C, ACT-
1,CMY-2,FOX-
1,MIR-1 
1e NI C Cephalosporins No No GC1,CMY-37 
2a 2a A Penicillins Yes No PC 1 
2b 2b A 
Penicillins and 
early 
cephalosporins 
Yes No 
TEM-1,TEM-2, 
SHV-1 
2be 2be A 
Extended 
spectrum 
cephalosporins 
,monobactams 
Yes No 
TEM-3,SHV-
2,CTX-M,PER-
1,VEB-1 
2br 2br A Penicillins No No  
2ber NI A 
Extended 
spectrum 
cephalosporins 
,monobactams 
No No TEM-50 
2c 2c A Carbenicillin Yes No  
2ce NI A 
Carbenicillin, 
Cefepime 
Yes No  
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2d 2d D Cloxacillin Variable No OXA-01,OXA-10 
2de NI D 
Extended 
spectrum 
cephalosporins 
Variable No OXA-11, OXA-15 
2df NI D Carbapenems Variable No OXA-23, OXA-48 
2e 2e A 
Extended 
spectrum 
cephalosporins 
Yes No Cep A 
2f 2f A Carbapenems Variable No 
KPC-2, SME-1. 
IMI-1 
3a 3 B(B1) Carbapenems No Yes 
IMP-1, VIM-1, 
CcrA, IND-1 
3b 3 B(B2) Carbapenems No Yes CphA, Sfh-1 
NI 4 Unknown     
 
DETECTION OF BETALACTAMASES 
 Biochemical tests are used to detect β lactamases. This acid production 
was measured by 
1. Acidometric method: change in pH of an indicator dye is measured. 
2. Iodometric method:  
3. Chromogenic cephalosporin method: 
 Normally Nitrocefin is yellow in colour which turns red on production of 
β-lactamases. 
β LACTAMASE INHIBITORS30 
 Beta lactamase inhibitors are enzymes that are similar to β lactam 
antibiotics. They bind either reversibly or irreversibly to beta lactamase, thereby 
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preventing β lactam antibiotics from destruction. They act as suicide bombers, 
utilizing all available enzymes. Clavulanic acid, Sulbactam and Tazobactam are 
some of the examples of beta lactamase inhibitors that have gained importance 
in clinical medicine. 
EXTENDED SPECTRUM BETALACTAMASE 
The ESBL enzymes are plasmid - mediated enzymes which hydrolyse and 
inactivate a number of betalactams, including third generation cephalosporins, 
penicillins and aztreonam.  These enzymes are included under the Group 2 Serine 
betalactamases. 
Subgroup 2a penicillinases have a narrow spectrum of activity against 
benzyl penicillin and penicillin derivatives in Gram positive cocci .They readily 
hydrolyse nitrocefin but have weak activity against Cephalosporin, Carbapenem 
or monobactam compounds. 
Sub group 2b includes plasmid mediated betalactamases coded by TEM-
1, TEM-2 and SHV-1 which hydrolyse penicillin and first generation 
cephalosporin and are inhibited by clavulanic acid and Tazobactam. 
Subgroup 2be includes enzymes which hydrolyse penicillins and first 
generation cephalosporins and in addition can hydrolyse one or more 
oximinobetalactams like ceftazidime, cefotaxime and aztreonam. This subgroup 
includes CTX-M enzymes which hydrolyse cefotaxime better than ceftazidime 
and have some activity against cefepime as well. They are inhibited by 
Tazobactam better than clavulanic acid. 
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Subgroup 2br enzymes consists of those enzymes that have activity 
similar to subgroup 2b but are resistant to Clavulanic acid and other 
betalactamase inhibitors. TEM enzymes (TEM 30 and 31) have been 
characterised in this group. 
Subgroup 2 ber is named as the complex mutant TEM (CMT) exhibit an 
extended spectrum beta lactamase activity with moderate resistance to clavulanic 
acid inhibition. 
Subgroup 2c hydrolyses carbenicillin or ticarcillin rapidly with weak 
hydrolysis of cloxacillin or oxacillin. 
Subgroup 2d betalactamases hydrolyse cloxacillin and oxacillin, hence 
named OXA enzymes. 
Subgroup 2 de betalactamases described from Pseudomonas aeruginosa 
in France and Turkey can hydrolyse cloxacillin or oxacillin along with extended 
spectrum activity against oximino betalactams. 
Subgroup 2df has carbapenem hydrolysing activity as well. 
 
DETECTION OF ESBL PRODUCTION [7][25][30] 
SCREENING FOR ESBL PRODUCTION 
1. DISC DIFFUSION METHOD 
A Mueller-Hinton agar is used for disc diffusion method of antibiotic 
susceptibility testing. The Mueller Hinton agar plate is inoculated with a swab 
submerged in a bacterial suspension standardized to 0.5 McFarland turbidity 
standard, in three directions. The antimicrobial disks are placed and the plates 
incubated for 16-18 hours at 35°C. 
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According to CLSI guidelines 2018, screening for ESBL production is 
done by detecting resistance to third generation cephalosporins by Kirby bauer 
disc diffusion method. The sensitivity of detection of ESBL is increased by using 
more than one antimicrobial agent for screening. 
For Klebsiella pneumoniae, Klebsiella oxytoca and Escherichia coli 
screening has to be performed with the following drugs[2]. 
DRUGS STRENGTH ZONE DIAMETER 
Cefpodoxime 10µg ≤ 17 mm 
Ceftazidime 30 µg ≤ 22 mm 
Aztreonam 30 µg ≤ 27 mm 
Cefotaxime 30 µg ≤ 27 mm 
Ceftriaxone 30 µg ≤ 25 mm 
 
For Proteus mirabilis screening has to be performed with the following 
drugs[2] 
DRUGS STRENGTH ZONE DIAMETER 
Cefpodoxime 10µg ≤ 22 mm 
Ceftazidime 30 µg ≤ 22 mm 
Cefotaxime 30 µg ≤ 27 mm 
 
2. BROTH MICRODILUTION[52][53][54]  
Cation adjusted Mueller Hinton Broth is used for screening of extended 
spectrum betalactamase producers by broth dilution.This test is done using a 
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microtitre plate onto which dilutions of the drug are dispensed. The standardized 
bacterial inoculum of 0.5 Mc Farland turbidity is inoculated into the different 
dilutions of the drug and incubated at 35 ° C for 16-18 hours.The minimum 
concentration of drug that inhibits the bacterial growth is identified as the 
minimum inhibitory concentration. 
 
According to CLSI guidelines, 2018 the screening for extended spectrum 
beta lactamase production is done for Klebsiella pneumoniae, Klebsiella oxytoca 
and Escherichia coli screening has to be performed with the following drugs 
DRUGS CONCENTRATION 
Cefpodoxime ≥ 4 µg/ml 
Ceftazidime ≥ 1 µg/ml 
Aztreonam ≥ 1 µg/ml 
Cefotaxime ≥ 1 µg/ml 
Ceftriaxone ≥ 1 µg/ml 
 
3. CHROMOGENIC MEDIA FOR ESBL DETECTION[56][66][85] 
This media uses a combination of chromogenic substrates which detect 
galactosidase or glucosidase production by Escherichia coli and glucosidase 
production by Klebsiella Enterobacter Serratia group thereby differentiating 
amongst the main groups producing urinary tract infection. A cephalosporin is 
added to inhibit the non ESBL producers and other inhibitors are added to 
prevent the growth of gram positive cocci and yeasts. Examples of chromogenic 
media to detect the chromID ESBL consisting of a Mac Conkey agar plate with 
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ceftazidime and cefotaxime and Brilliance ESBL consisting of a MacConkey 
agar with ceftazidime disk. 
CONFIRMATORY TESTS FOR EXTENDED SPECTRUM BETA 
LACTAMASE DETECTION [2][85] 
Confirmation of extended spectrum beta lactamase production is done 
using two third generation cephalosporins alone and in combination with a beta 
lactamase inhibitor. According to CLSI, 2018 two methods can be used for the 
confirmation of extended spectrum beta lactamase production. 
1. Disc diffusion method 
2. Broth microdilution method 
 
 DISC DIFFUSION METHOD 
DRUG STRENGTH INTERPRETATION 
Ceftazidime 
Ceftazidime- clavulanate 
30 µg 
30/10 µg 
≥ 5mm increase in zone 
diameter of either antimicrobial 
agent tested in combination 
with clavulanate vs the zone 
diameter when tested alone 
indicates positive ESBL 
production. 
Cefotaxime 
Cefotaxime – clavulanate 
30 µg 
30/10 µg 
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BROTH MICRODILUTION METHOD 
DRUG STRENGTH INTERPRETATION 
Ceftazidime 
Ceftazidime- clavulanate 
0.25-128 µg/ml 
0.25/4 -128/4 µg/ml 
≥ 3 fold concentration decrease in 
an MIC for either antimicrobial 
agent tested in combination with 
clavulanate vs the zone diameter 
when tested alone indicates 
positive ESBL production. 
Cefotaxime 
Cefotaxime - clavulanate 
0.25-64 µg/ml 
0.25/4 - 64/4 µg/ml 
 
OTHER TESTS FOR DETECTION OF EXTENDED SPECTRUM 
BETALACTAMASE 
1. EPSILOMETER TEST( E – TEST )[85] 
This test uses the disc diffusion principle and can determine the minimum 
inhibitory concentration of the drug with respect to the test organism. It consists 
of a plastic strip having an antimicrobial concentration gradient labelled with the 
specific drug concentrations numerically[86]A Mueller Hinton Agar plate is 
inoculated with a lawn culture of the test organism and the E-strip is kept on it. 
This plate is incubated overnight and the border of growth inhibition which 
intersects the E- strip is taken as the minimum inhibitory concentration. 
 
 
 
 
37 
 
2. AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TEST 
SYSTEMS[85] 
1. Vitek 2 systems  
A miniaturized, plastic, 64-well, closed card containing specified 
concentrations of antibiotics is inoculated with the bacterial suspension by a 
filling tube and incubated at specific temperature. The amount of light 
transmitted through each well including the growth control well is measured by 
optical density readings taken every 15 minutes. The growth curve is analysed 
by the system’s software and validated by Advanced Expert System (AES) 
software. AES software reports resistance organisms based on MIC.The average 
time taken for this instrument is 6-8 hours. 
 
2. MicroScan WalkAway system  
It works based on the broth microdilution panel format. It is inoculated 
manually using a multiprong device. This panel is incubated in an incubator 
reader unit and growth patterns are read and interpreted using spectrophotometry 
or fluorometry. 
 
3. Phoenix system 
Manual inoculation is done and growth is detected using a redox indicator 
system. Supplemental testing for ESBL is included, hence reducing repeat 
testing of the isolates. The results are available within 8-12 hours. 
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GENOTYPIC DETECTION OF EXTENDED SPECTRUM BETA 
LACTAMASE 
Specific primers have been developed to detect the various ESBL genes 
including TEM, SHV, OXA, CTX-M, and GES enzymes in gram-negative 
bacteria. Molecular methods which can be used for detection on ESBL genes 
include 
1. Conventional PCR 
2. Real -time PCR assay 
3. Multiplex PCR 
4. DNA microarrays  
 
AmpC BETALACTAMASES 
AmpC betalactamases are enzymes that confer resistance to betalactams 
including betalactam – betalactamase combination. Inducible chromosomal 
Amp C enzymes are found in the SPICE group of Enterobacteraciae which 
includes Serratia marcesans, Proteus mirabilis, Citrobacter fruendii and 
Enterobacter cloacae. Plasmid mediated Amp C enzymes exhibit resistance to 
cefamycins as well which include cefoxitin and cefotetan. 
 
DETECTION OF Amp C PRODUCTION[2] 
Diagnostic tests for Amp C detection are based on use of inhibitors of 
Amp C (EDTA, cloxacillin, and various boronic acid derivatives).The only 
commercially available inhibitor of Amp C is 3-amino phenyl boronic acid and 
is used in the detection. 
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SCREENING FOR Amp C PRODUCTION[2] 
Cefoxitin resistance detected during antimicrobial susceptibility testing is 
used as a screening test for Amp C production. The antimicrobial susceptibility 
is tested using a cefoxitin disc (30 µg) and a zone diameter of ≤ 14 mm is 
considered resistant. 
 
CONFIRMATORY TESTING FOR Amp C PRODUCTION [2] 
COMBINED DISC DIFFUSION TEST[41] 
The test is done using an antimicrobial susceptibility tested with cefoxitin 
disc (30 µg) alone and in combination with phenyl boronic acid (400 µg). The 
zone diameter of both the discs are measured and ≥ 5mm increase of zone 
diameter in the presence of phenyl boronic acid is considered positive for Amp 
C beta lactamase production. This test can also be done with cefpodoxime alone 
and with cloxacillin. 
 
Amp C DISC TEST[52] 
A Muller Hinton agar plate is inoculated with a lawn culture of 
Escherichia coli ATCC 25922. A sterile disc (6 mm) is placed next to the 
Cefoxitin disc. It is moistened with sterile saline, and inoculated with colonies 
of the test organism. The plate was incubated overnight at 35 ̊°C for 16-18 hours. 
A flattening or indentation of the cefoxitin inhibition zone near the test disc 
indicates a positive test. A complete zone around the Cefoxitin shows a negative 
test. 
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AmpC E TEST STRIP  
The E strip to test Amp C is commenrcially available as a plastic strip 
containing a concentration gradient of cefotetan on one-half of the strip and 
cefotetan with cloxacillin on the other half of the strip. 
MIC value difference of ≥ 8 between cefotetan and cefotetan with 
colxacillin is considered positive for Amp C. 
 
GENOTYPIC TESTING OF Amp C 
The gold standard test for confirmation of Amp C is based on molecular 
methods of detection. Phenotypic testing methods are unable to differentiate 
between plasmid mediated and chromosomal Amp C enzyme production.  
CARBAPENEMASE PRODUCTION 
These enzymes are capable of hydrolysing the carbapenem antibiotics by 
specific enzymes. According to the molecular classification of betalactamases 
by Ambler they belong to class A,B and D 
BETALACTAMASE 
CLASS 
ORGANISMS GENES 
Class A 
K. pneumoniae 
Enterobacteriaceae 
KPC, SME, NMC-A, IMI, 
PER, GES, SFO, SFC,IBC 
Class B 
Enterobacteriaceae 
P. aeruginosa 
A. baumannii 
VIM, IMP, NDM, SPM, 
SIM, GIM 
Class D 
Enterobacteriaceae 
A. baumannii 
OXA-48 
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The classes A and D are serine carbapenemases while the class B are 
metallobetalactamases requiring Zinc ion for the hydrolysis of the carbapenems. 
This form of resistance mechanism is typically plasmid mediated .Most of these 
carbapenemase genes are neither species nor plasmid specific and leading to 
extensive the spread of such resistance. The Ambler group B or Bush Jacoby 
group 3 hydrolyse carbapenems but have poor action on monobactams.  
These enzymes are not inhibited by tazobactam or clavulanic acid but are 
inhibited by dipicolonic acid, EDTA or 1,10-phenanthroline.Amongst group 3, 
two functional groups are proposed  
 
Subgroup 3 a:  
It includes the IMP and VIM family that are inhibited by dipicolonic acid. 
These enzymes have a broad spectrum of action against antibiotics including 
penicillin, cephalosporin and carbapenem but not monobactam compounds. 
 
Subgroup 3 b: 
Hydrolyses only carbapenems, hence not detected by the chromogenic 
cephalosporin substrate (Nitrocephin test)  
 
DETECTION OF CARBAPENEMASE PRODUCTION 
SCREENING TEST FOR CARBAPENEMASES 
1. DISC DIFFUSION TEST 
Carbapenemase producing isolates are detected to have a zone diameter 
which falls under intermediate or resistant category as per CLSI, 2018 
guidelines. The isolates may also show resistance to one or more third generation 
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cephalosporins. Ertapenem resistance is considered as the most sensitive 
indicator of carbapenemase production.[2] 
 
DRUG 
DISC 
STRENGTH 
RESISTANT 
ZONE 
DIAMETER 
MIC 
Ertapenem 10 µg ≤ 18 2-4 µg 
Meropenem 10 µg ≤ 19 2-4 µg 
Imipenem 10 µg ≤ 19 2 µg 
 
2. CHROMOGENIC MEDIA FOR CARBAPENEMASE PRODUCTION 
Synthetic chromogenic enzyme substrates are incorporated into media to 
identify the organisms based on their enzymatic action. 
 
The incorporation of the carbapenems (imipenem or ertapenem or 
meropenem) into the medium along with the specific substrates for the 
enterobacteraciae allows for selective growth of carbapenem resistant 
organisms.Examples of such media include CHROMagar KPC containing Mac 
Conkey agar with Imipenem, chromID CARBA containing Mac Conkey agar 
and meropenem, chromID OXA-48 containing Trypticase soy broth with 
Ertapenem and Brilliance CRE agar containing Macoconkey agar with 
imipenem or ertapenem. 
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CONFIRMATION OF CARBAPENEMASE PRODUCTION 
1. Modified Carbapenem Inactivation test(mCIM)[2,36] 
1µL loop full of bacteria from an overnight culture is inoculated into 2ml 
of trypticase soy broth. A 10µg Meropenem disc is immersed in this trypticase 
soy broth and incubated at 35°C ± 2 °C for 4 hours ± 15 minutes. This 
meropenem disc is placed in a lawn culture of ATCC Escherichia coli 25922 and 
incubated at 35 ± 2 °C for 18-24 hours. 
 
A zone diameter of 6-15 mm or presence of pinpoint colonies within 16-
18 mm zone is considered positive for carbapenemase production. A zone 
diameter of ≥ 19 mm is considered negative for carbapenemase production.[2] 
 
2. EDTA MODIFIED CARBAPENEM INACTIVATION METHOD (eCIM)  
20 µL of 0.5 M EDTA is added to 2ml Trypsticase soy broth to which 
1µL loop full bacteria is added and the same procedure as mCIM is performed. 
A ≥ 5mm increase in zone diameter of meropenem when compared to mCIM is 
considered positive for carbapenemase production.[2] 
 
3. CARBA NP test[2,31,34,37,38,39,40] 
It uses the principle of hydrolysis of imipenem by the carbapenemases in 
the presence of zinc followed by detection using colorimetric pH indicators. 
There are two versions of this test:- 
 CARBA NP I : Detects the presence of carbapenemase and gives a 
positive or negative result 
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 CARBA NP II: Detects and discriminates between carbapenemases class 
A,B or D.  
 
CARBA NP I 
 Two microcentrifuge tubes labelled ‘a’ and ‘b’ are required for each 
patient isolate, quality control and reagent control 
 100 µL of the bacterial protein extraction reagent is added to each tube 
 A 1 µL loopful of bacteria are added into both tubes ‘a’ and ‘b’ 
 100 µL of solution A (containing Zinc sulfate, Phenol red and Sodium 
hydroxide) is added to tube ‘a’ 
 100 µL of solution B (solution A with imipenem) is added to tube ‘b’. 
 Incubate at 35°C for 2 hours 
 
INTERPRETATION 
1. Uninoculated reagent control tubes should be red/ orange for the test to 
be valid. 
2. Inoculated tubes : 
a) Tube ‘a’ – should be red or orange for the test to be valid 
b) Tube ‘b’ – 
 Red or red-orange color indicates that the test organism is negative for 
carbapenemase production 
 Light orange, dark yellow or yellow colour indicates that the test 
organism is positive for carbapenemase production.[2] 
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3. GENOTYPIC DETECTION OF CARBAPENEMASES 
The gold standard test for carbapenemase detection is based on Molecular 
methods which include:- 
 Conventional Polymerase chain reaction 
 Real time Polymerase chain reaction 
 Multiplex Polymerase chain reaction for blaKPC, blaNDM and blaVIM 
carbapenem resistance gene[87] 
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MATERIALS AND METHODS 
 
This cross sectional study was conducted in the Department of 
Microbiology, Government Kilpauk Medical college and Hospital, Chennai for 
a period of 1 year from June 2017 to May, 2018 to study the bacterial isolates 
causing urinary tract infection in patients with type 2 diabetes mellitus. A total 
of 305 samples were collected from patients with type 2 diabetes mellitus 
attending the diabetology out patient department. 
 
INCLUSION CRITERIA: 
 Patients identified to have type 2 Diabetes mellitus 
 Both male and female patients 
 Ambulent patients 
 
EXCLUSION CRITERIA: 
 Non diabetics 
 Type 1 Diabetes mellitus 
 Patients on antibiotics for the past 1 week 
 Patients on urinary catheter 
 
SAMPLE COLLECTION 
A total of 305 urine samples were collected from patients with type 2 
diabetes mellitus who were symptomatic or asymptomatic for urinary tract 
infection in the Institute of Diabetology, Government Kilpauk Medical College. 
Informed consent was obtained and the patients were instructed on the proper 
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urine sample collection technique. The urine samples were collected using mid 
stream clean catch urine sample collection into a sterile wide mouthed 
container.2 mid stream clean catch urine samples were collected from patients 
asymptomatic of urinary tract infection who were culture positive. 
 
TRANSPORT OF URINE SAMPLES 
The specimens were transported to the laboratory and processed within 2 
hours of collection of sample. 
 
PROCESSING OF URINE SAMPLE 
The urine sample was divided into two portions. The first portion was 
used for urine microscopy and culture and the other portion was used for 
commercial reagent strip test for the nitrite and leucocyte esterase.  
 
MACROSCOPIC APPEARANCE[86] 
The urine sample is assessed for the following parameters 
1. Colour 
2. Turbidity 
3. Visible Blood 
The results were recorded. 
 
COMMERCIAL REAGENT STRIP 
The kit instructions were followed for the reagent strip test and the result 
was obtained by comparing the colour of the test strip to the reference colour 
code provided with the strip within 30 -60 seconds. The results were recorded. 
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MICROSCOPIC EXAMINATION 
WET MOUNT[85] 
0.05 ml of well mixed uncentrifuged urine is placed on the centre of the 
slide and a coverslip is placed over it immediately. This preparation is observed 
under high power objective (x 40).The presence of ≥ 1 leucocyte per 7 HPF 
indicated pyuria. 
 
GRAM STAIN[86][86] 
A drop of well-mixed urine is smeared onto the slide and allowed to air-
dry, the smear is heat fixed, stained, and examined under oil immersion (1000×) 
for the presence of 1 bacteria per oil immersion field (OIF). 
 
URINE CULTURE [85][86] 
Semi Quantitative Method 
The uncentrifuged urine was mixed well and the calibrated loop is 
inserted vertically into the container. The urine is streaked onto Nutrient agar, 
5% sheep Blood agar, Mac Conkey agar and Cysteine Lactose Electrolyte 
Deficient agar vertically in the centre followed by horizontal streaks which 
intersect the vertical streak line, without flaming in between each streak. The 
culture plates are incubated at 35°C overnight. 
 
Interpretation of urine culture [85] 
Based on the laboratory findings in the semiquantitative culture it is 
interpreted as follows:[85] 
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COLONY 
COLONY 
COUNT 
INTERPRETATION 
A single colony 
isolated 
≤105 CFU Growth insignificant 
≥ 105 CFU 
Significant growth and proceed with 
identification and antibiotic sensitivity 
2 organisms 
isolated 
Both 
organisms ≥ 
105 CFU 
Significant growth and process with 
identification and antibiotic susceptibility 
testing for both organisms 
Two organisms 
with one 
predominant 
isolate 
One isolate 
≥ 105 CFU 
Process with identification and antibiotic 
sensitivity testing for the predominant 
isolate 
3 or more 
organisms 
 
Mixed growth, considered as a 
contamination 
 
The organisms were identified based on standard microbiological 
procedures and antibiotic susceptibility performed by Kirby Bauer disk diffusion 
method. The antibiotic susceptibility was performed for Ampicillin, Gentamicin, 
Amikacin, Amoxicillin clavulanate, Piperacillin Tazobactam, Cefepime, 
Cefoxitin, Cefotaxime, Ceftazidime, Ciprofloxacin, Meropenem, cotrimoxazole, 
Nitrofurantoin and Norfloxacin. 
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DETECTION OF EXTENDED SPECTRUM BETA LACTAMASE 
SCREENING FOR ESBL PRODUCTION [2][7][25][30][52] 
The production of extended spectrum betalactalactamases is done 
according to CLSI, 2018 criteria by performing Kirby Bauer disc diffusion test 
with the following drugs. 
 
DRUGS CONCENTRATION ZONE SIZE 
Ceftazidime 30 µg ≤ 22mm 
Cefotaxime 30 µg ≤ 25mm 
 
CONFIRMATION OF ESBL PRODUCTION[2][7][25][30][52] 
1. Phenotypic Confirmation By Disc Diffusion Method 
Disc diffusion method was used for the phenotypic confirmation of extended 
spectrum betalactamase production. 
 
DRUG STRENGTH INTERPRETATION 
Ceftazidime 
Ceftazidime- clavulanate 
30 µg 
30/10 µg 
≥ 5mm increase in zone 
diameter of either 
antimicrobial agent tested 
in combination with 
clavulanate verses the zone 
diameter when tested alone 
indicates positive ESBL 
production. 
Cefotaxime 
Cefotaxime – clavulanate 
30 µg 
30/10 µg 
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DETECTION OF AmpC PRODUCTION [2,5,6,7,25,26] 
SCREENING TEST FOR Amp C 
The screening test for Amp C production is done by testing for resistance 
to cefoxitin. . The antimicrobial susceptibility was tested using a cefoxitin disc 
(30 µg) and a zone diameter of ≤ 14 mm is considered resistant. 
 
CONFIRMATORY TEST FOR Amp C 
Lawn culture of Escherichia coli ATCC 25922 was done on Mueller-
Hinton agar. Cefoxitin(30µg) disc was placed on it. Sterile disks (6mm) were 
moistened with sterile saline (20µl) and inoculated with several colonies of test 
organism. The inoculated disc was then placed beside cefoxitin disc (almost 
touching) on the inoculated plate. The plate was incubated at 35ºC for16-18 
hours. Flattening or indentation of the cefoxitin inhibition zone in the vicinity of 
the test organism disc was taken as positive for AmpC Disc test, negative test 
had a distorted zone, 
 
DETECTION OF CARBAPENEMASE PRODUCTION [2][26][27][44][46] 
SCREENING TEST FOR CARBAPENEMASES 
DISC DIFFUSION TEST 
Carbapenemase producing isolates are detected to have a zone diameter 
which falls under intermediate or resistant category as per CLSI, 2018 
guidelines. The isolates may also show resistance to one or more third generation 
cephalosporins. Ertapenem resistance is considered as the most sensitive 
indicator of carbapenemase production.[2] 
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DRUG 
DISC 
STRENGTH 
RESISTANT 
ZONE 
DIAMETER 
MIC 
Ertapenem 10 µg ≤ 18 2-4 µg 
Meropenem 10 µg ≤ 19 2-4 µg 
Imipenem 10 µg ≤ 19 2 µg 
 
CONFIRMATION OF CARBAPENEMASE PRODUCTION 
Modified Carbapenem Inactivation test (mCIM)[2][36] 
1µL loop full of bacteria from an overnight culture is inoculated into 2ml 
of trypticase soy broth. A 10µg Meropenem disc is immersed in this trypticase 
soy broth and incubated at 35°C ± 2 °C for 4 hours ± 15 minutes. This 
meropenem disc is placed in a lawn culture of ATCC Escherichia coli 25922 and 
incubated at 35 ± 2 °C for 18-24 hours. 
A zone diameter of 6-15 mm or presence of pinpoint colonies within 16-
18 mm zone is considered positive for carbapenemase production. A zone 
diameter of ≥ 19 mm is considered negative for carbapenemase production.[2] 
 
GENOTYPIC CONFIRMATION OF ESBL, Amp C AND MBL 
PureFast® Bacterial DNA minispin purification kit [Kit contains 
Lysozyme, Lysozyme digestion buffer, Proteinase-K, Binding buffer, Wash 
Buffer-1, Wash Buffer-2, Spin columns with collection tube and elution buffer. 
HELINI 2X ReDdye PCR Master Mix, Agarose gel electrophoresis consumables 
and Primers are from HELINI Biomolecules, Chennai, India. 
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2X Master Mix: 
It contains 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM MgCl2, 
1μl of 10mM dNTPs mix and RedDye PCR additives. 
Agarose gel electrophoresis: 
Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide are from 
HELINI Biomolecules, Chennai. 
 
PCR: 
HELINI Ready to use blaTEM gene Primer mix - 5μl/reaction 
PCR Product: 260bp 
HELINI Ready to use blaCTX-M gene Primer mix - 5μl/reaction 
PCR Product: 295bp 
HELINI Ready to use ampC gene Primer mix - 5μl/reaction 
PCR Product: 125bp 
HELINI Ready to use IMP gene Primer mix - 5μl/reaction 
PCR Product: 387bp 
HELINI Ready to use VIM gene Primer mix - 5μl/reaction 
PCR Product: 125bp 
HELINI Ready to use NDM gene Primer mix - 5μl/reaction 
PCR Product: 202bp 
Bacterial DNA Purification 
1. 1ml of overnight culture centrifuged at 6000rpm for 5min 
2. Supernatant discarded 
3. Pellet is suspended in 0.2ml PBS. 
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4. 180μl of Lysozyme digestion buffer and 20μl of Lysozyme 
[10mg/ml] added. 
5. Incubated at 37C for 15min. 
6. 400μl of Binding buffer, 5μl of internal control template and 20μl of 
Proteinase K added, Mixed well by inverting several times. 
7. Incubate at 56ºC for 15min. 
8. Added 300μl of Ethanol and mixed well. 
9. Transferred entire sample into the PureFast® spin column. 
Centrifuged for 1 min. Discard the flow-through and place the 
column back into the same collection tube. 
10. Added 500μl Wash buffer-1 to the PureFast® spin column. 
Centrifuge for 30-60 seconds and discard the flow-through. Place 
the column back into the same collection tube. 
11. Added 500μl Wash buffer-2 to the PureFast® spin column. 
Centrifuge for 30-60 seconds and discard the flow-through. Place 
the column back into the same collection tube. 
12. Discard the flow-through and centrifuge for an additional 1 min. 
This step is essential to avoid residual ethanol. 
13.  Transferred the PureFast® spin column into a fresh 1.5 ml micro-
centrifuge tube. 
14. Added 100μl of Elution Buffer to the center of PureFast® spin 
column membrane. 
15. Incubate for 1 min at room temperature and centrifuge for 2 min. 
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16. Discard the column and store the purified DNA at -20°C. Quality 
and Quantity of extracted DNA is checked by loading in 1% agarose 
gel and 5μl of extracted DNA is used for PCR amplification. 
 
PCR Procedure: 
1. Reactions set up as follows; 
Components Quantity 
HELINI RedDye PCR Master mix 10μl 
HELINI Ready to use - Primer Mix 5μl 
Purified Bacterial DNA 5μl 
Total volume 20μl 
 
2. Mixed gently and spin down briefly. 
 
3. The PCR machine is loaded and programmed as follows; 
Initial Denaturation: 95ºC for 5 min 
Denaturation: 94ºC for 30sec 
Annealing: 58ºC for 30sec 35 cycles 
Extension: 72ºC for 30sec 
Final extension: 72º C for 5 min 
 
Loading: 
1. Prepared 2% agarose gel. [In 100ml of 1X TAE buffer, 2gm of agarose is 
added] 
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2. Run electrophoresis at 50V till the dye reaches three fourth distances and 
observe the bands in UV Transilluminator. 
 
Agarose gel electrophoresis: 
1. Prepared 2% agarose. (2gm agarose in 100ml of 1X TAE buffer and 
melted using micro oven) 
2. 5μl of Ethidium bromide is added when the agarose gel temperature 
reaches around 60ºC. 
3. Warm agarose solution is poured slowly into the gel platform. 
4. The gel is allowed to set till the agarose solidifies. 
5. Poured 1XTAE buffer into submarine gel tank. 
6. Carefully placed the gel platform into tank. Maintained the tank buffer 
level 0.5cm above than the gel. 
7. PCR Samples are loaded after mixed with gel loading dye along with 10μl 
HELINI 100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 
600bp, 700bp, 800bp, 900bp, 1000bp and 1500bp] 
8. Electrophoresis is run at 50V till the dye covers three fourth distance of 
the gel. 
9. Gel viewed in UV Transilluminator and observed the bands pattern 
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RESULTS 
 
A total of 305 urine samples were collected from patients with type 2 
diabetes mellitus in The Institute of Diabetology, Government Kilpauk Medical 
College and Hospital. The patients were categorised as symptomatic and 
asymptomatic for urinary tract infection. The screening, culture and antibiotic 
susceptibility testing was performed for all the samples. Amongst the isolated 
organisms, Gram Negative bacteria were analysed for extended spectrum beta 
lactamase, Amp C betalactamase and metallo betalactamase production. The 
study was conducted for a period of one year from June 2017 to May 2018. 
The observations were recorded and analysed. The results were as 
follows: 
Table No 1: Distribution of Type 2 Diabetes mellitus patients included in the 
study with respect to gender. 
Patient Male Female Total 
Symptomatic of UTI 34 108 142 
Asymptomatic of UTI 37 126 163 
Total patients 71 234 305 
The patients with Type 2 Diabetes mellitus were tested for urinary tract 
infection and categorised as symptomatic and asymptomatic of UTI. The number 
of symptomatic patients included was 142 and asymptomatic patients included 
was 163.The number of female patients were more when compared to the male 
patients in the study. The value of Chi square test was 0.066 and P-value > 0.05 
in this table hence the difference is statistically insignificant. 
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Table No: 2 Age And Sex Distribution Of Patients With Type 2 Diabetes 
Mellitus. 
 
Age 
Distribution 
Symptomatic 
Patients 
(n=142) 
Asymptomatic 
Patients 
(n=163) 
Total 
Patients 
(n=305) 
 M F Total M F Total M F TOTAL 
31-40 4 14 18 5 14 19 9 28 37 
41-50 5 37 42 10 33 43 15 70 85 
51-60 6 32 38 12 52 64 18 84 102 
61-70 11 18 29 9 20 29 20 38 58 
71-80 8 7 15 1 7 8 9 14 23 
 
 
The number of patients from the age group 51- 60 years is more in 
asymptomatic UTI patients while in symptomatic UTI patients is more in 41-50 
years age group.  
 
Amongst the total patients tested, the maximum urine samples are from 
51 – 60 years age group. The Chi square test value for this table was 7.386 and 
P-value > 0.05, hence the difference is statistically insignificant. 
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Table No: 3 Symptoms pertaining to urinary tract infection in patients with type 
2 diabetes mellitus. 
Symptom No: of Patients 
Dysuria 86 (60.6%) 
Frequency of urination 51(35.9%) 
Fever 32(22.5%) 
Lower Abdominal pain 22(15.4%) 
Itching 17(11.9%) 
 
The most common symptom pertaining to urinary tract infection 
presented in the diabetic patients was dysuria ( 60.6%) followed by frequency of 
urination(35.9%).Dysuria with frequency of urination was seen in 10 
patients(7.1%),dysuria with fever in 11 patients(7.7%),Dysuria with suprapubic 
pain in 8 patients(5.6%) and dysuria with itching in 2 patients (1.4%).  
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Table No: 4 Results of Screening tests for all the urine samples collected in 
Patients with Diabetes mellitus 
Screening 
test 
Symptomatic 
of UTI 
(n = 142) 
Asymptomatic 
of UTI 
(n = 163) 
Total Urine 
samples 
(n = 305) 
X2 P-value 
Pus cells 33(23.2%) 31(19 %) 64(26.2%) 0.386 >0.05 
Nitrate 
reduction 
18(12.7%) 11(6.7%) 29(0.3%) 1.874 >0.05 
Leukocyte 
esterase 
28(19.7%) 18(11.1%) 46(15%) 3.208 >0.05 
Direct gram 
stain 
50(35.2%) 37(22.7%) 87(28.5%) 4.664 <0.05* 
 
Amongst all the urine samples collected (n= 305), Direct gram stain was 
positive in 87 urine samples (28.5%) in total. In patients symptomatic of urinary 
tract infection, direct gram stain was positive in 50 samples(35.2%) and in 
patients asymptomatic of urinary tract infection, in 37 samples(22.7%). 
 
Pus cells were detected in 33 samples(23.2% ) of symptomatic UTI, 31 
urine samples(19% ) in asymptomatic UTI and in 64 samples (26.2%) of the total 
urine samples collected. Nitrate reductase was positive in 18 symptomatic 
patients(12.7%),11 asymptomatic patients (6.7%) and 29 of the total patients 
(0.3%).Leukocyte esterase was positive in 28 symptomatic patients (19.7%),18 
asymptomatic patients(11.1%) and 46 of the total urine samples (15%). 
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The p value calculated for the Direct gram stain is < 0.05 and hence is 
statistically significant while for the Pus cells , Leukocyte esterase and Nitrate 
reductase ,the P value was >0.05 and hence statistically insignificant. 
 
Table No:5 Results of Screening test among the culture positive urine samples 
from patients with type 2 Diabetes mellitus. 
 
Screening test 
Culture Positive 
Urine Samples 
(n = 93) 
Sensitivity Specificity 
Pus cells 54 (58.1%) 53.5% 95.1% 
Nitrate reductase 25 (26.9%) 23% 97% 
Leukocyte esterase 42 (45.2 %) 39.6% 97% 
Direct gram stain 80 (86.1%) 77.3% 95.59% 
 
Pus cells were observed in 54 culture positive urine samples (58.1%) from 
patients with type 2 diabetes mellitus. In the rapid card test positive results for 
nitrate reductase was seen in 25 samples (26.9%) and leukocyte esterase in 42 
(45.2%) culture positive urine samples. Direct gram stain was positive in 80 
culture positive urine samples (86.1%). 
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Table No:6 Culture positivity in urine samples from patients with Type 2 
Diabetes mellitus. 
Type Of Patients Culture Positivity 
Symptomatic of UTI(n= 142) 54 (38.1%) 
Asymptomatic of UTI (n=163) 39 (23.9%) 
Total patients( n= 305) 93 (30.5%) 
The culture positivity in urine samples collected from the patients with 
type 2 diabetes mellitus is 30.5%. Amongst patients symptomatic of UTI, culture 
positivity was 54(38.1%) and in asymptomatic patients was 39(23.9%). Co 
infection with 2 organisms was observed in 5 Out of the 93 culture positive 
samples,77 (82.7%) were from female and 16(17.2%)  were from male patients. 
The Chi square test value for this table was 7.12 and P-value < 0.05, hence the 
difference is statistically significant. 
 
Table No: 7 Distribution of Gram Positive and Gram Negative bacteria isolated 
from patients with Type 2 Diabetes mellitus  
 
Organisms isolated 
from Symptomatic 
UTI (n=59 ) 
Organisms isolated from 
Asymptomatic UTI 
(n=39) 
Total organisms 
isolated 
(n= 98) 
Gram Negative 
Bacteria 
40(67.8%) 22 (56.4%) 62 (63.3%) 
Gram Positive 
Bacteria 
19 (32.2%) 17(43.6%) 36(36.7%) 
Amongst the organisms isolated from the urine samples collected, 62 
isolates (63.3%) were Gram Negative Bacteria and 36 isolates( 36.7% ) were 
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Gram Positive bacteria. A total of 40 Gram Negative Bacilli (67.8%) and 19 
Gram Positive Cocci (32.2%) were isolated from symptomatic cases and a total 
of 22 Gram Negative Bacilli (56.4%) and 17 Gram Positive Cocci (43.6%) were 
isolated from asymptomatic patients. 
 
The Chi square test value for this table was 1.309 and P-value < 0.05, 
hence the difference is statistically significant 
 
Table No 8: Bacteriological Profile of organisms isolated from patients with 
Type 2 Diabetes mellitus with Urinary Tract Infection. 
 
Organism 
Symptomatic UTI 
(N=59) 
Asymptomatic 
UTI (N= 39) 
Total 
(N= 98) 
Escherichia coli 25(42.3%) 17(43.5%) 42(42.8%) 
Staphylococcus aureus 12 (20.3%) 7 (17.9%) 19(19.4%) 
Enterococcus faecalis 5 (8.4%) 8 (20.5%) 13(13.2%) 
Klebsiella pneumoniae 9(15.2%) 4 (10.2%) 13(13.9%) 
Proteus mirabilis 2(3.3%) 0 2(2.02%) 
Acinetobacter baumannii 2 (3.3%) 0 2(2.02%) 
Pseudomonas aeruginosa 2 (3.3%) 1 (0.02%) 3(3.2%) 
CONS 2 (3.3%) 2 (0.05%) 4(4.3%) 
TOTAL 59 39 98 
 
Amongst the organisms isolated from the urine samples collected, 
42(45.2%) isolates were Escherichia coli,19(19.4%) were Staphylococcus 
aureus, 13 (13.2%) were Enterococcus faecalis, 13 (13.9%) were Klebsiella 
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pneumoniae, 4(4.3%) were Coagulase Negative Staphylococcus, 3(3.2%) were 
Pseudomonas aeruginosa, 2(2.02%) were Acinetobacter baumannii and Proteus 
mirabilis each. 
Amongst the organisms isolated from symptomatic cases, the most 
common was Escherichia coli (25 isolates, 42.3%) followed by Staphylococcus 
aureus (12 isolates, 20.3%) and Klebsiella pneumoniae (9 isolates, 15.2%). In 
asymptomatic patients, the most common organism isolated was Escherichia coli 
(17 isolates, 43.5%) followed by Enterococcus faecalis (8 isolates, 20.5%) and 
Staphylococcus aureus (7 isolates, 17.9%). 
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Table No: 9 Antibiotic Susceptibility Pattern Of the organisms belonging to the 
Family Enterobacteriaciae, isolated from urine samples of patients with Type 2 
Diabetes mellitus. 
Drug E.coli (n= 42) K.pneumoniae (n = 13) P.mirabilis(n = 2) 
GROUP A 
Ampicillin 20(47.6%) IR* 2 
Gentamicin 38(90.5%) 12(92.3%) 2 
GROUP B 
Amikacin 41(97.6%) 13(100%) 2 
Amoxicillin 
clavulanate 
26(61.9%) 6(46.2%) 2 
Cefepime 23(54.7%) 8(61.5%) 2 
Cefoxitin 38(90.5%) 12(92.3%) 2 
Cefotaxime 19(45.2%) 7(53.8%) 1 
Ciprofloxacin 37(88.1%) 12(92.3%) 2 
Cotrimoxazole 22(52.4%) 8(61.5%) 1 
Meropenem 39(92.8%) 12(92.3%) 2 
Piperacillin 
Tazobactam 
37(88.1%) 13(100%) 2 
GROUP C 
Ceftazidime 16(38.1%) 9(69.2%) 2 
GROUP U 
Nitrofurantoin 15(35.7%) 8(61.5%) IR 
GROUP O 
Norfloxacin 28(66.6%) 7(53.8%) 0 
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In both symptomatic and asymptomatic patients, the Enterobacteriaciae 
isolated showed highest sensitivity to Amikacin, Meropenem, Piperacillin 
tazobactam followed by gentamicin and least susceptibility to Nitrofurantoin. 
 
Table No:10 Antibiotic susceptibility pattern of Non fermenters isolated from 
urine of patients with Type 2 Diabetes mellitus. 
Drugs 
Pseudomonas 
aeruginosa (n= 3) 
Acinetobacter 
baumannii (n= 2) 
GROUP A 
Piperacillin 
Tazobactam 
3 2 
Gentamicin 3 2 
Ceftazidime 3 1 
GROUP B 
Amikacin 3 2 
Cefepime 3 2 
Ciprofloxacin* 1 0 
Meropenem* 2 2 
Cotrimoxazole IR** 0 
Nitrofurantoin 2 1 
Norfloxacin 3 2 
*Group A drugs for Acinetobacter baumannii 
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The nonfermenting gram negative bacteria isolated from urinary tract 
infection in patients with Type 2 Diabetes mellitus showed 100% sensitivity to 
Piperacillin Tazobactam, Cefepime, Norfloxacin, Amikacin and Gentamicin and 
least susceptible to Ciprofloxacin. 
 
Table No: 11 Antibiotic Sensitivity Pattern Of Gram Positive Cocci Isolated 
from urine samples of patients with type 2 Diabetes mellitus. 
Drug 
Staphylococcus 
aureus (n=19) 
E.faecalis 
(n=13) 
CONS 
(n=4) 
GROUP A    
Penicillin 10(55.5%) 8(61.5%) 4(100%) 
Amoxicillin 
clavulanate 
9(50%) IR* 3(75%) 
Cefoxitin 14(77.7%) IR* 4(100%) 
Erythromycin 13(72.2%) IR* 4(100%) 
Clindamycin 13(72.2%) 9(69.2%) 4(100%) 
Cotrimoxazole 11(61.1%) IR* 4(100%) 
Ampicillin NA 8(61.5%) NA 
GROUP U    
Nitrofurantoin 13(72.2%) 11(84.6%) 4(100%) 
GROUP C    
High level 
Gentamicin 
NA 9(69.2%) NA 
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The Staphylococcus aureus isolated showed maximum susceptibility to 
Nitrofurantoin, Erythromycin and Clindamycin and least to Penicillin. Out of the 
19 Staphylococcus aureus isolated, 4 (21%) were found to be Methicillin 
Resistant Staphylococcus aureus based on Cefoxitin disc screening method. All 
the 4 MRSA isolated were detected from symptomatic UTI patients. The MRSA 
isolated was susceptible to Vancomycin.  
 
The Enterococcus faecalis isolated, showed highest sensitivity to 
Nitrofurantoin and least sensitivity for Penicillin. 
 
Table No: 12 Extended spectrum betalactamase enzyme production detected in 
Gram Negative organisms isolated from urine samples of patients with Type 2 
Diabetes mellitus patients. 
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Screening Test 
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Disc 
diffusion 
23 
(54.8%) 
2 
(15.4%) 
0 0 0 
ESBL 
Confirmatory 
Test Positive 
DDST 20(47.6%) 1 (7.7%) 0 0 0 
E-strip 
20 
(47.6%) 
1 
(7.7%) 
0 0 0 
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Amongst the Gram Negative bacteria isolated from urinary tract infection 
in type 2 diabetes mellitus patients, a total of 21 (33.9%) isolates were detected 
to have ESBL production. Out of the 21 ESBL positive isolates, 10 Escherichia 
coli(16.1%) were isolated from symptomatic UTI patients and the remaining 10 
Escherichia coli (16.1%) and 1 Klebsiella pneumoniae (1.6%) was isolated from 
asymptomatic UTI patients. Hence, the prevalence of ESBL amongst 
symptomatic UTI is 25% and in asymptomatic patients was 50%. The P- value 
calculated for the tests from the table were <0.05 and hence were statistically 
significant. 
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Table No: 13 Antibiotic susceptibility pattern of ESBL producing Escherichia 
coli isolated from urine samples of patients with Type 2 Diabetes mellitus. 
 
Drug Escherichia coli(N = 20) 
GROUP A  
Ampicillin 0 
Gentamicin 18 (90%) 
GROUP B  
Amikacin 20 (100%) 
Amoxicillin clavulanate 10 (50%) 
Cefepime 12 (60%) 
Cefoxitin 18 (90%) 
Ciprofloxacin 15 (75%) 
Cotrimoxazole 9 (45%) 
Nitrofurantoin 14 (70%) 
Norfloxacin 11 (55%) 
Piperacillin Tazobactam 20 (100%) 
Meropenem 17 (85%) 
 
Amongst the Escherichia coli isolated from symptomatic patients, 100% 
sensitivity was seen to Piperacillin Tazobactam and Amikacin while least 
susceptibility (40%) was seen to Cotrimoxazole and Ampicillin. One ESBL 
positive isolate of Klebsiella pneumoniae was highest sensitive to Meropenem, 
Piperacillin Tazobactam, Amikacin and Gentamicin. 
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Table No: 14 Amp C producing organisms isolated from urine samples of 
patients with Type 2 Diabetes mellitus. 
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Amongst the Gram Negative bacilli isolated, 11 isolates (17.7%) were 
phenotypically confirmed Amp C producers including 8 Escherichia coli isolates 
and 3 Klebsiella pneumoniae isolates. Amongst the 11 Amp C positive isolates, 
5 (including 3 Escherichia coli and 2 Klebsiella pneumoniae) were isolated from 
symptomatic UTI and 6 (including 5 Escherichia coli and 1 Klebsiella 
pneumoniae) were isolated from asymptomatic UTI patients. Hence, the 
prevalence of Amp C production in symptomatic UTI was 12.5% and in 
asymptomatic patients was 27.3%. 
 
  
CHART - 12 
 
 
CHART - 13 
 
0
10
20
30
40
50
60
70
E.coli(n= 42) K.pneumoniae(n=13) Total GNB
AmpC PRODUCTION DETECTED AMONGST ISOLATES FROM 
URINARY TRACT INFECTION IN PATIENTS WITH TYPE 2 
DIABETES MELLITUS
AmpC PRODUCERS TOTAL ISOLATES
0
1
2
3
4
5
6
7
8
9
E.coli K.pneumoniae
Ampicillin Gentamicin Amikacin Amoxicillin clavulanate
Cefepime Cefotaxime Ceftazidime Ciprofloxacin
Cotrimoxazole Nitrofurantoin Norloxacin Piperacillin tazobactam
Meropenem
72 
 
Table No: 15 Antibiotic susceptibility pattern of Amp C positive isolates from 
patients with Type 2 Diabetes and UTI 
 
Antibiotic Tested E. coli(n=8) K.pneumoniae(n= 3) 
Ampicillin 0 IR 
Gentamicin 8(100%) 1 
Amikacin 8(100%) 1 
Amoxicillin clavulanate 2(25%) 1 
Cefepime 8(100%) 1 
Cefotaxime 2(33.3%) 3 
Ceftazidime 2(33.3%) 3 
Ciprofloxacin 4(66.6%) 1 
Cotrimoxazole 2(2 1 
Nitrofurantoin 6(33.3%) 3 
Norfloxacin 5(66.6%) 3 
Piperacillin Tazobactam 3(37.5%) 3 
Meropenem 7(87.5%) 3 
 
The isolates of Amp C producing Escherichia coli show 100% 
susceptibility to Amikacin, Gentamicin and Cefepime. In Amp C positive 
Klebsiella pneumoniae isolated, highest susceptibility to Meropenem, 
Norfloxacin, Nitrofurantoin, Ceftazidime and Cefotaxime was observed. One 
isolate of Escherichia coli amongst the organisms isolated from symptomatic 
patients was resistant to Meropenem.  
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Table No: 16 MBL production among Gram Negative bacterial isolates from 
urine samples from patients with Type 2 Diabetes mellitus patients. 
Test 
Total Isolates Tested For MBL Production (N= 62) 
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Amongst the Gram Negative bacilli isolated, 6 isolates (4 Escherichia coli 
1 Pseudomonas aeruginosa and 1 Klebsiella pneumoniae) were positive by 
screening for Metallobetalactamase production. Out of the 6 screening positive 
isolates, 3 isolates (4.8%) including 2 Escherichia coli and 1 Pseudomonas 
aeruginosa were phenotypically confirmed as metallobetalactamase producers 
all of which were isolated from Type 2 Diabetes mellitus patients symptomatic 
of UTI. The p- value calculated for the Confirmatory tests is <0.05 and hence 
significant. 
 
CHART - 14 
 
 
CHART - 15 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
E.coli P.aeruginosa K.pneumoniae
MBL PRODUCERS DETECTED AMONGST UTI 
ISOLATES FROM PATIENTS WITH 
TYPE 2 DIABETES MELLITUS
Screening test Confirmatory tests
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
ESBL E.coli Amp C E.coli MBL E.coli ESBL+ Amp C E.coli ESBL+ MBL E.coli
RESISTANCE PROFILE OF ESCHERICHIA COLI 
ISOLATED FROM URINE SAMPLES OF PATIENTS 
WITH TYPE 2 DIABETES MELLITUS
RESISTANT E.coli TOTAL E.coli
74 
 
Amongst the MBL producing Escherichia coli isolates, 100% sensitivity 
was seen to Piperacillin Tazobactam, Ciprofloxacin, Amikacin and Gentamicin. 
All MBL producing E.coli isolates were resistant to Ceftazidime, Cefotaxime, 
Cefepime, Amoxicillin clavulanate and Ampicillin. The MBL positive 
Pseudomonas aeruginosa isolate was 100% sensitive to Piperacillin 
Tazobactam, Ceftazidime, Amikacin, Gentamicin and Norfloxacin and resistant 
to Ciprofloxacin and Cefepime. All the MBL positive isolates were 100% 
sensitive to colistin. 
 
CO EXPRESSION OF RESISTANCE PATTERNS 
The co expression of ESBL with Amp C was detected in 4 Escherichia 
coli isolated from 2 symptomatic and 2 asymptomatic patients. The coexpression 
of both ESBL and MBL was detected in 2 E.coli isolated from symptomatic 
patients. 
Table No: 17 Genotypic characterisation of ESBL positive isolates from Urine 
samples in patients with Type 2 Diabetes mellitus. 
 
Organism Total No: 
Tested 
blaCTX-M 
positive 
blaTEM 
positive 
blaSHV 
positve 
E.coli 7 7 7 Not tested 
K.pneumoniae 1 Not tested 1 1 
 
Out of the total of 20 ESBL positive Escherichia coli isolates, 7 isolates 
were tested genotypically for the ESBL coding genes blaCTX-M and blaTEM. All 
the 7 ESBL positive E.coli isolates tested were positive for blaCTX-M and blaTEM 
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genes. One ESBL positive Klebsiella pneumoniae isolate by phenotypic method 
was tested and found positive for blaTEM and blaSHV genes.  
 
Table No:18 Genotypic characterisation of Amp C positive isolates from urine 
samples from patients with Type 2 Diabetes mellitus 
 
Organism Total No: Tested blaAmp C positive 
E.coli 5 5 
K.pneumoniae 2 2 
 
Amongst the 8 AmpC positive Escherichia coli isolates, 5 isolates were 
tested for the presence of bla Amp C. Amongst the 3 Amp C positive Klebsiella 
pneumoniae isolates, 2 were tested for blaAmp C gene. The blaAmp C gene was 
positive for the 5 E.coli and 2 K.pneumoniae tested.   
 
Table No: 19 Genotypic characterisation of MBL positive isolates from urine 
samples from patients with Type 2 Diabetes mellitus. 
ORGANISM 
TOTAL NO: 
tested 
blaNDM 
positive 
blaVIM 
positive 
E.coli 2 2 - 
P.aeruginosa 1 1 0 
 
Amongst the 3 MBL producers idenified, 2 E.coli and 1 Pseudomonas 
aeruginosa tested were positive for blaNDM gene. None of the isolates were 
positive for blaVIM gene. 
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POLYMERASE CHAIN REACTION FOR bla CTX-M 
 
C1, C2, C3, C4, positive for bla CTX-M – 295bp 
 
POLYMERASE CHAIN REACTION FOR bla TEM 
 
T1, T2, T3, T4, T5, positive for bla TEM – 260bp 
 
POLYMERASE CHAIN REACTION FOR bla SHV AND bla VIM 
 
S1, S2, positive for bla SHV – 471bp 
V1,V2 positive for bla VIM – 125bp 
 
 
Ladder C 1 C 2 C 3 C 4 
Ladder T 1 T 2 T 3 T 4 T 5 
Ladder S 1 S 2 V 1 V 2 
NTC 
  
 
POLYMERASE CHAIN REACTION FOR bla AmpC 
 
A1, A2, A3, A4, positive for bla AmpC – 125bp 
 
 
POLYMERASE CHAIN REACTION FOR bla NDM 
 
N1, N2, N3 positive for bla NDM – 202bp 
 
 
 
 
Ladder A 1 A 2 A 3 A 4 
Ladder N 1 N 2 N 3 NTC 
  
 
 
 
EPSILOMETER TEST (E TEST) FOR COLISTIN SENSITIVITY 
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DISCUSSION 
 
The aim of this study is to isolate the bacteria producing urinary tract 
infection in patients with type 2 diabetes mellitus and identify the resistance 
profile of these bacteria including the expression of extended spectrum 
betalactamases, Amp C betalactamases and metallobetalactamases. This study 
was conducted for a period of 1 year, from June2017 to May 2018 among 305 
patients with type 2 Diabetes mellitus who were categorised according to the 
presence or absence of symptoms of urinary tract infection. 
 
Patients with Type 2 Diabetes mellitus presenting with complaints of 
dysuria, frequency of urination, lower abdominal pain who were culture positive 
were taken as Symptomatic urinary tract infection. Urinary tract infection proven 
by culture positivity in 2 urine samples amongst Type 2 diabetes mellitus in the 
absence of symptoms was considered as Asymptomatic bacteriuria. 
 
As per Table no: 1,in the study 142 patients (46.5%) with Type 2 diabetes 
mellitus symptomatic of Urinary tract infection and 163 patients (53.4%) 
asymptomatic of urinary tract infection were included. There are more number 
of female patients in Type 2 Diabetes mellitus patients both with symptoms and 
asymptomatic of urinary tract infection. This is similar to the study done by 
Janifer J et al [1] where 60% patients were symptomatic of UTI and 40% were 
asymptomatic of Urinary tract infection. 
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As per Table no: 2, the number of patients in the age group 51- 60 years 
was more in asymptomatic UTI patients while in symptomatic UTI, patients in 
the age group 41-50 years was higher. This is similar to the study done by 
Eshwarappa et al [8] showing a higher prevalence of urinary tract infection in the 
age group 50-79 years. 
 
As per table no:3, dysuria (60.6%) was the most common presenting 
complaint followed by frequency of urination (35.9%). This is similar to the 
study done by Eshwarappa et al [8] and Sadhna Sharma et al [14]  
 
As per table No: 4 the direct gram stain and detection of pus cells were 
positive in 28.5% patients and 26.2% patients respectively. This is lower than 
that reported by Jay F.Lewis et al [19] showing an 89% positivity of gram stain. 
 
As per table no: 5, amongst the culture positive urine specimens, the direct 
gram stain was positive in 86.1% samples and pus cells were positive in 58.1% 
patients. This is in concurrence with the study done by Jay F. Lewis et al [19] 
showing a gram stain positivity of 89% in culture positive samples. The Direct 
Gram stain could detect the presence of significant bacteriuria in 86.1% patients 
with urinary tract infection, hence can be used as an effective screening method 
on the basis of which empirical therapy for Urinary tract infection can be started.  
 
As per table No: 6, the prevalence of urinary tract infection in patients 
with Type 2 Diabetes mellitus is 30.5% amongst which symptomatic individuals 
is 38.02% and in asymptomatic individuals is 23.9%.This is in concordance with 
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Singhal et al[16] with asymptomatic bacteriuria at 28.2% and Suzanne E 
Geerlings et al [50] and lesser than the study by Kalpana Devi Venkatesan et al[17] 
at 32%.The prevalence of urinary tract infection in type 2 diabetic patients 
symptomatic of UTI was 43% as per the study conducted by Sadhna Sharma et 
al[14] and is 26% in asymptomatic patients as per the study done by Huvos et al[61] 
which is similar to the results obtained in this study. The patients with Type 2 
diabetes mellitus may have symptoms similar to urinary tract infection due to 
other causes as well like Benign prostatic hypertrophy in men and leukorrhea or 
vaginitis in women. Diabetic patients have a tendency to develop neurological 
dysfunctions like autonomic neuropathy, hence there may be non specific 
symptoms similar to urinary tract infection. This may be the reason why all the 
symptomatic patients were not culture positive.  
 
As per table no:7, amongst the organisms grown in symptomatic UTI 
patients, 69.4% were Gram Negative bacilli and 30.5% were Gram Positive cocci 
whereas in asymptomatic patients 56.4% were Gram Negative bacilli and 43.5% 
were Gram Positive cocci. This is in concordance with the study done by 
Kalpana Devi Venkatesan et al [17] with 68.8% GNB and 31.3% GPC in 
asymptomatic individuals. This is in concordance with the study done by 
Bhumika Vaishnav et al [60] in which 70% of organisms isolated from type 2 
diabetic patients symptomatic of urinary tract infections were Gram Negative 
bacteria. Asymptomatic bacteriuria remains largely undetected and is frequently 
followed by symptomatic urinary tract infection with complications.  
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According to Table No: 8, in symptomatic patients the distribution of 
organisms is E.coli 47.4%, K.pneumoniae 15.2%, P.aeruginosa 0.03%, 
P.mirabilis 0.03%,S.aureus 18.6%, Enterococcus faecalis 0.08% and CONS 
(0.03%). In asymptomatic Patients, 43.5% was E.coli, 0.2% K.pneumoniae, 
0.02% P.aeruginosa, 17.9% S.aureus, 20.5% Enterococcus faecalis and 0.05% 
CONS. Therefore the most common organism is Escherichia coli followed by 
Staphylococcus aureus and Klebsiella pneumoniae in Symptomatic UTI patients 
and E.coli followed by Enterococcus faecalis and Staphylococcus aureus in 
Asymptomatic patients. This is different from the study done by Niranjan et al 
[57] which shows E.coli as the most predominant followed by Klebsiella 
pneumoniae and Pseudomonas aeruginosa. This study is correlating with the 
study done by Vaishnav et al[60] which shows the most common organism as 
Escherichia coli followed by Candida, Enterococcus and Staphylococcus 
species. The study correlates with a study done by Marie E.A.Bissong [15] 
showing the increased prevalence of Staphylocoocci followed by E.coli, 
Klebsiella, Candida and Serratia species. An increase in the urinary tract 
infection produced by Gram Positive cocci has been observed in this study. 
 
As per Table No:9, amongst the Enterobacteriaciae isolated highest 
sensitivity was seen to Amikacin, Meropenem, Piperacillin tazobactam followed 
by gentamicin and least susceptibility to Nitrofurantoin. This study correlates 
with the study done by Stephenson et al [21] with resistance of 21.8% to 
cefotaxime, 78.2% to Ciprofloxacin and 43.1% to Cotrimoxazole. This study 
shows higher values than the study done by Veeraraghavan et al[47] with 
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sensitivity to Ceftazidime 33%,Cefotaxime 24%,Cefepime 28%, Ciprofloxacin 
21%, Amikacin 81%, Piperacillin Tazobactam 66% and Imipenem 76%.This is 
higher than the study done by Jharna Mandal et al [58] with a sensitivity of 57% 
resistance to Ceftazidime, 59.6% to Gentamicin, 73% to Ciprofloxacin and 23% 
to Amikacin. The sensitivity pattern observed is similar to M.Eshwarappa et al[8] 
with least resistance to carbapenems followed by Amikacin. Hence , considering 
the antibiotic susceptibility profile of the organisms isolated, amongst the first 
line antibiotics prescribed for urinary tract infection, Nitrofurantoin and amongst 
the second line agents , Amikacin are good options for therapy in Urinary tract 
infection amongst patients with Type 2 Diabetes mellitus. 
 
As per Table No: 10, amongst the non-fermenters identified in 
Pseudomonas aeruginosa 100% sensitivity was observed to Ceftazidime, 
Gentamicin, Amikacin and Cefepime which is similar to the study done by Richa 
Gupta et al[30] showing maximum susceptibility to Piperacillin, eftazidime, 
Cefepime, Amikacin, Gentamicin and Levofloxacin. In Acinetobacter baumanii 
isolates, the maximum sensitivity was seen to Piperacillin Tazobactam, 
Ceftazidime, Cefepime, Amikacin, Gentamicin, Meropenem and Norfloxacin. 
This is different from the study done by Richa Gupta et al [30] showing 
Acinetobacter spp showing maximum sensitivity to Ceftazidime clavulanic acid, 
Gentamicin and levofloxacin. The number of non fermenters isolated from urine 
samples in this study are lesser compared to the Enterobacteriaciae family and 
yet,1 Pseudomonas aeruginosa isolate amongst the symptomatic UTI patients 
was positive for MBL production. The prevalence of MBL production amongst 
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non fermenters from urinary tract infection cannot be commented upon here as 
the number of isolates in this study is less.  
 
As per Table No: 11, among the 18 Staphylococcus aureus isolated, 4 
isolates (22.2%) were Methicillin resistant Staphylococcus aureus from patients 
symptomatic of UTI. This is lower than that reported in the study by Robert R. 
Muder et al [18]. 
 
As per table 12, a total of 21 (33.9%) isolates were detected to have ESBL 
production. Out of the 21 ESBL positive isolates, 10 Escherichia coli (16.1%) 
were isolated from symptomatic UTI patients and the remaining 10 Escherichia 
coli (16.1%) and 1 Klebsiella pneumoniae (1.6%) was isolated from 
asymptomatic UTI patients. This is similar to the study done by Pottahil Shinu 
et al [7] showing 35% ESBL production. This study is also in concordance with 
the study done by Sam Stephenson et al [21] showing 31% and Maninder Kaur et 
al [63] showing 45.63% prevalence of ESBL producers. The ESBL prevalence in 
this study is lower than those done by Eshwarappa et al[8] showing 42.2% ESBL 
positivity in E.coli and 9.6% in Klebsiella pneumoniae, Nandagopal et al[22] 
showing 64%, Anand Prakash Maurya et al showing 58.67% and A.Manoharan 
et al [64] showing 78%. In my study the overall expression of ESBL in 
symptomatic UTI was 18.6% and amongst asymptomatic UTI was 28.2% 
indicating the increased expression of ESBL resistance pattern in the patients 
asymptomatic of UTI. 
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As per Table No: 13, the ESBL positive isolates amongst the symptomatic 
patients showed the maximum sensitivity to Piperacillin Tazobactam and 
Amikacin followed by Gentamicin, Ciprofloxacin and Meropenem. The least 
sensitivity was seen with Nitrofurantoin, Norfloxacin, Amoxicillin clavulanic 
acid showing 50% sensitivity and Cotrimoxazole showing 40% sensitivity. This 
is similar to the study done by E A George et al [29] showing highest susceptibility 
to Piperacillin Tazobactam, Meropenem, Amikacin and Tigecycline. This is 
similar to the study done by A.Manoharan et al [64] showing 100% susceptibility 
to Imipenem, Meropenem, 89% to Amikacin and 85% to Piperacillin 
tazobactam. 
 
As per Table No:14, amongst the E.coli isolated 12% were found to be 
Amp C producers by screening and phenotypic confirmatory testing. Amongst 
the Klebsiella pneumoniae isolated, 22.2% were detected to be Amp C 
producers. This is similar to the study done by Hemalatha et al [5] showing 9.2% 
pure Amp C expression, by Anand Manoharan et al [41] showing 12.5% 
prevalence of Amp C production, by Pottahil Shinu et al [7] showing 8% Amp C 
expression in E.coli and RM Shoorashetty et al [25] showing 6%. The prevalence 
of Amp C producers amongst Klebsiella isolated in this study is similar to the 
study done by M.Shanthi et al [6] showing 23% Amp C expression. This study 
shows a lower production of Amp C as compared to the study done by Arindam 
Chakraborty et al [43] showing a prevalence of 29.5% of Amp C producers. 
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According to the study, expression of Amp C is more in organisms 
isolated from asymptomatic UTI (27.3%) as compared to symptomatic UTI 
(12.1%). 
 
Co expression of ESBL with Amp C was observed in 4 E.coli isolated 
(9.5%) which is similar to that reported by Varsha Gupta et al [55] with 8%, 
Gaurav Dalela et al [52] showing 4.1% coexpression and Jaspal Kaur et al [54] 
showing 5.4% coexpression of ESBL with Amp C. This study shows a higher 
prevalence of co expression of ESBL with Amp C as compared to the study by 
Pottahil Shinu[7] et al showing 3.08% co existence of ESBL and Amp C in E.coli. 
The co expression of resistance profiles was detected only in Symptomatic UTI 
patients in this study which indicates a necessity for early detection and treatment 
of urinary tract infection in patients with Type 2 diabetes mellitus when they 
present with symptoms of Urinary tract infection. 
 
As per Table No:15, the maximum sensitivity amongst Amp C producing 
E.coli was seen to Amikacin, Gentamicin and Cefepime and least sensitivity was 
seen to Cefotaxime and Ceftazidime. Amongst the Amp C producing Klebsiella 
pneumoniae, the maximum sensitivity was seen to Meropenem, Cefotaxime, 
Ceftazidime, Nitrofurantoin and Norfloxacin. This is similar to the study by 
Anand Manoharan et al [41] showing maximum sensitivity to Imipenem, 
Meropenem, Amikacin and Piperacillin Tazobactam. 
 
As per Table No: 16, 6 isolates (4 Escherichia coli, 1 Pseudomonas 
aeruginosa and 1 Klebsiella pneumoniae) were positive by screening for 
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Metallobetalactamase production out of the which 3 isolates (4.8%) including 2 
Escherichia coli and 1 Pseudomonas aeruginosa were phenotypically confirmed 
as metallobetalactamase producers. All the MBL positive isolates were detected 
amongst patients symptomatic of UTI. This is similar to the study done by Bora 
A et al [35] showing a prevalence of 5.18% of MBL production in Escherichia 
coli. This study shows a lower prevalence of MBL than the study done by V V 
Borah et al [27] showing a prevalence of 18.8% metallobetalactamase producers 
in E.coli and the study done by Balvinder Mohan et al [28] showing a prevalence 
of 12.3% of metallobetalactamase producers. Hence, the resistance to 
Carbapenems in more amongst the symptomatic UTI. 
 
As per the study, the coexpression of ESBL with MBL was detected in 2 
E.coli isolates (4.7%). This is lower than that observed by V.V.Borah et al [27] 
showing 69.2% coexistence of ESBL and MBL. 
 
As per Table No: 17, 7 phenotypically confirmed isolates of ESBL 
producing E.coli tested showed 100% positivity for the presence of both CTX -
M and TEM genes.1 ESBL producing Klebsiella pneumoniae isolated from 
symptomatic patients was genotypically tested for TEM and SHV both of which 
were found to be positive. This is similar to the study done by B.Nandagopal et 
al[22] ,EA George et al [24] and Maninder Kaur et al [63] showing maximum 
prevalence of CTX-M and TEM amongst ESBL producers. This is in contrast to 
the study done by Manoharan et al [64] showing CTX -M and TEM positivity of 
39.2% amongst ESBL producers. Hence the phenotypic confirmatory test for 
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ESBL production correlates well with the genotypic test indicating that the 
phenotypic tests are sufficient in resource poor settings for routine evaluation of 
ESBL production. 
 
As per Table 18, 5 E.coli and 2 Klebsiella pneumoniae isolates which 
were phenotypically confirmed as Amp C producers showed 100% Amp C gene 
positivity. This is higher than that observed in the study by A Manoharan et al 
[26] showing 46% blaAmp C positivity among Amp C producing E.coli. 
 
As per Table No: 19, amongst the organisms isolated, 2 isolates of E.coli 
were positive for NDM gene and 1 isolate of Pseudomonas aeruginosa tested for 
NDM and VIM gene showed positivity only for NDM gene. This is similar to 
the study by V V Borah et al [27] showing maximum positivity for NDM gene 
expression amongst E.coli. This indicates a high prevalence of NDM gene in the 
MBL producers isolated from urinary tract infection in patients with type 2 
diabetes mellitus. 
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SUMMARY 
 
 In the study, 305 urine samples were collected from patients with type 2 
diabetes mellitus. 
 Direct Gram stain showed a sensitivity of 77.3% and specificity of 95.6% 
with a concordance with culture positivity of 86% hence can be used as 
an effective screening tool for urinary tract infection in Type 2 Diabetes 
mellitus patients.  
 The prevalence of Urinary tract infection in Type 2 Diabetes mellitus 
patients was 30.5%.The prevalence of symptomatic UTI was 38.1% and 
asymptomatic UTI was 23.9%. 
 The most common isolate amongst the culture positive urine isolates was 
Escherichia coli (42.8%). In Symptomatic UTI, E.coli was followed by 
Staphylococcus aureus and Klebsiella pneumoniae in prevalence but in 
asymptomatic UTI, E.coli was followed by Enterococcus faecalis and 
Staphylococcus aureus in prevalence. 
 The increase in the prevalence of Gram Positive cocci producing UTI 
warrants the use of antimicrobial agents that have action on both Gram 
positive and Gram negative bacteria such as Nitrofurantoin. 
 The Gram Negative Bacilli isolated showed maximum sensitivity to 
Amikacin and Meropenem. 
 Amongst the Gram Negative bacteria isolated, the prevalence of ESBL 
was 33.9%, Amp C was 17.7% and MBL was 4.8%. 
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 The resistance patterns observed showed a higher prevalence in isolates 
from asymptomatic UTI as compared to symptomatic UTI with respect to 
ESBL and Amp C.ESBL production in patients symptomatic of UTI was 
25% while in asymptomatic UTI it was 50%.Amp C production detected 
in Symptomatic UTI was 12.5% while in asymptomatic UTI was 27.3%. 
 Coexpression of ESBL with Amp C was observed in 6.4% isolates and 
ESBL with MBL were observed in 3.2% isolates from symptomatic UTI. 
 The isolates were genotypically confirmed for ESBL(bla CTX-M, blaTEM 
and blaSHV), Amp C(blaAmpC) and MBL production (blaNDM, blaVIM) 
 Out of the 8 ESBL producing isolates tested, bla CTX-M, blaTEM were 
positive in 7 Escherichia coli and blaTEM and blaSHV genes in 1 Klebsiella 
pneumoniae. 
 Amongst the 7 Amp C producing isolates tested, all were positive for 
blaAmpC gene 
 Amongst the 3 MBL producers tested (2 Escherichia coli and 1 
Pseudomonas aeruginosa), all were positive for blaNDM and were negative 
for bla VIM. 
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CONCLUSION 
 
This study highlights the presence of a significant number of isolates 
showing resistant patterns amongst the organisms isolated from Urinary Tract 
infections in patients with type 2 diabetes mellitus. This is cause for caution 
amongst these patients, especially amongst the asymptomatic patients. Hence, 
periodic screening for urinary tract infection in type 2 diabetes mellitus patients 
irrespective of the symptoms will be helpful in the early detection and treatment 
of urinary tract infection, thereby reducing the morbidity and mortality of the 
patients with Type 2 Diabetes mellitus. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
PROFORMA 
Name :   
Age/Sex: 
Lab. No: 
IP / OP No: 
Duration of diabetes: 
Type of diabetes: 
History of presenting illness: 
Symptoms of UTI: 
 Fever 
 Dysuria 
 Suprapubic pain 
 Frequency of urination 
 Itching 
Associated illnesses: 
Family history: 
Microscopic Finding 
Direct Gram Stain 
Wet mount 
Culture Characteristics 
Nutrient Agar 
Blood agar 
CLED Agar 
Biochemical Reactions: 
Antibiotic Susceptibility Pattern: 
ESBL 
Amp C 
MBL 
 
 
Signature of Investigator    Signature of the Guide 
 
PATIENT CONSENT FORM 
 
BACTERIOLOGICAL PROFILE AND DETECTION OF ESBL, Amp C AND  
METALLO-β-LACTAMASES IN TYPE 2 DIABETES PATIENTS WITH 
URINARY TRACT INFECTION 
 
STUDY CENTER: 
KILPAUK MEDICAL COLLEGE AND HOSPITAL, CHENNAI. 
PATIENT NAME:       PATIENT AGE: 
IDENTIFICATION NUMBER: 
PATIENT TO TICK (        )THESE BOXES  
 
I confirm that I have understood the purpose of procedure for the above study.  
I have the opportunity to ask the question and all my questions and doubts have 
been answered to my satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at anytime without giving any reasons, without my legal rights being affected. 
I understand that investigator, regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to the current 
study and any further research that may be conducted in relation to it, even if withdraw 
from the study, I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from the study. 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperative with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or wellbeing or any 
unexpected or unusual symptoms. 
I hereby give consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic test. 
 
Place:                     Signature/Thumb impression: 
Date: 
 
Patient name and address:     Signature of the investigator:
  
      
Place:                Study investigator’s name: 
Date: 
 
 
 
சுயஒப்புதல்படிவம் 
 
ஆய்வு செய்யப்படும் தலைப்பு: BACTERIOLOGICAL PROFILE AND 
DETECTION OF ESBL, Amp C AND METALLO-β-LACTAMASES IN TYPE 2 
DIABETIC PATIENTS WITH URINARY TRACT INFECTION 
 
ஆய்வு செய்யப்படும் இடம்: கீழ்பாக்கம் அரசு மருத்துவக்கல்லூரி மற்றும் மருத்துவமலை, 
சென்லை-10 
பங்குசபறுபவரின் சபயர்: 
பங்குசபறுபவரின் வயது:                                           பங்குசபறுபவரின் எண் : 
 
மமமை குறிப்பிட்டுள்ள மருத்துவ ஆய்வின் விவரங்கள் எைக்கு 
விளக்கபட்டுள்ளது. நான் இவ்வாய்வில் தன்னிச்லெயாக பங்மகற்கின்மேன். எந்த 
காரணத்திைாமைா, எந்த ெட்டசிக்கலுக்கும் உட்படாமல் நான் இவ்வாய்வில் இருந்து 
விைகிக்சகாள்ளைாம் என்றும் அறிந்து சகாண்மடன். 
 
இந்த ஆய்வு ெம்பந்தமாகமவா, இலத ொர்ந்து மமலும் ஆய்வு மமற்சகாள்ளும் 
மபாதும் இந்த ஆய்வில் பங்குசபறும் மருத்துவர் என்னுலடய மருத்துவர் என்னுலடய 
மருத்துவ அறிக்லககலள பார்ப்பதற்கு என் அனுமதி மதலவ இல்லை எை அறிந்து 
சகாள்கிமேன்.  
 
இந்த ஆய்வின் மூைம் கிலடக்கும் தகவலைமயா, முடிலவமயா 
பயன்படுத்திக்சகாள்ள மறுக்கமாட்மடன். 
 
இந்த ஆய்வில் பங்குசகாள்ள ஒப்புக்சகாள்கிமேன். இந்த ஆய்லவ மமற்சகாள்ளும் 
மருத்துவ அணிக்கு உண்லமயுடன் இருப்மபன் என்று உறுதியளிக்கிமேன். 
 
பங்மகற்பவரின் லகசயாப்பம்:                                                  ொட்சியாளரின் லகசயாப்பம் 
இடம்:                                                                                      இடம்: 
மததி:                                                                                      மததி : 
பங்மகற்பவரின் சபயர் மற்றும் விைாெம்: 
 
APPENDIX 
PEPTONE WATER 
Peptone                -     10g  
Sodium chloride         -     5g  
Distilled water           -     1 litre 
 
Dissolve the ingredients in warm water, adjust the pH to 7.4 -7.5 and filter. 
Distribute as required and autoclave at 121 degree Celsius for 15 mins. 
 
BLOOD AGAR 
Sterile sheep blood             -      50 ml  
Peptone                      -     10 g  
Beef extract                  -     3g  
Sodium chloride               -      5 g  
Distilled water                 -     1000 ml 
 
Autoclave the nutrient agar base at 121º C for 15 minutes and blood with sterile 
precautions and distribute in Petri dishes. 
 
MAC CONKEY AGAR 
Peptic digest of animal tissue     -     17g  
Proteose peptone               -     3g  
Lactose                      -     10g  
Bile salts                     -     1.5g  
Sodium chloride               -     5g  
Neutral red                   -     0.03g 
Agar                        -     15g 
Distilled water                -     1000 ml 
Final pH at (25º C) 7.1±0.2. 
 
Suspend 51.53 grams in 1000 ml of distilled water. Heat to boiling to dissolve 
the medium completely. Sterilize by autoclaving at 15 lbs pressure (121ºC) for 15 
minutes. Mix well and pour into Petri dish plates. 
 
NUTRIENT AGAR 
Peptic digest of animal tissue          -     5g  
Beef extract                       -     1.5g  
Yeast extract                       -     5g  
Agar                             -     15g 
Distilled water                     -     1000ml 
 
Dissolve the contents in water and mix by heating. Autoclave at 121° C for 15 
minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml of 9 cm diameter. Petri dishes to give 
4 mm thickness 
 
Cystine lactose electrolyte deficient No. 30 
(CLED medium)  
This medium is best prepared from ready to use dehydrated powder, available from 
most suppliers of culture media. 
 
 
 
Contents: 
Peptone, Lab-Lemco powder, tryptone, lactose,L-cystine, bromothymol blue, 
agar. 
 
The medium is usually used at a concentration of 18.1 g in every 500 ml distilled 
water (concentration may vary depending on manufacturer). 
1 Prepare as instructed by the manufacturer.Sterilize by autoclaving at 121 ° C for 15 
minutes. 
2 Mix well before pouring (avoid air bubbles forming). Dispense aseptically in 15 ml 
amounts in sterile petri dishes as described in subunit 7.4. 
3 Date the medium and give it a batch number. 
4 Store the plates at 2–8 ° C, preferably sealed in plastic bags to prevent loss of moisture. 
 
Shelf-life: Up to 4 weeks or longer provided there is no change in the appearance of the 
medium to suggest contamination or a change in pH. 
pH of medium: This should be within the range pH 7.3–7.5 at room temperature. 
 
1. OXIDASE TEST 
This test is mainly done to differentiate organisms lacking cytochrome oxidase 
enzyme, mainly the members of enterobactericeae. This enzyme helps in the transfer of 
electrons to oxygen, with formation of water. The dye tetramethyl paraphenylene 
diamine dihydrochloride is substituted for oxygen as artificial electron acceptor. In the 
reduced state, it is colorless and in the presence of cytochrome oxidase and oxygen it 
forms indophenol, which is purple. Strips impregnated with dried reagents were used. 
The colony was taken on a wooden stick and smeared onto the strip. The appearance of 
purple color within 10 sec. was taken as positive. 
2. CATALASE TEST  
Organisms’ possessing the enzyme catalase splits hydrogen peroxide into water 
and oxygen. The evolution of oxygen appears as bubbles. Tube catalse test was 
performed 3ml of 3% Hydrogen peroxide was taken in a test tube. The colony of the 
organism to be tested was taken on a glass rod and introduced into the tube. Appearance 
of brisk effervescence was taken as positive. 
3. MOTILITY 
Motility was done by hanging drop method. A drop of saline with the test 
organism was placed on the coverslip. The hanging drop slide is inverted over the 
coverslip where wax had been applied on the corners. The slide is turned quickly so that 
drop is in centre of the concavity. The edge of the drop is focused on the low power and 
high power objectives. Motility was observed. 
4. INDOLE TEST 
Indole is a benzyl pyroll which is a metabolic product of tryptophan. Bacteria 
which  possess  tryptophanase  hydrolyse  trytophan  to  indole.  The organism was 
inoculated in peptone water medium, incubated at 37
0
C for 18-24 hours, 1ml of zylene 
was added and Erlichs’reagent (Para dimethyl amino benzaldehyde) was added drop by 
drop. Formation of fuchsia red ring was positive. It is a red complex of indole and 
paradimethylaminobenzaldehyde. 
5. TRIPLE SUGAR IRON MEDIUM  
Triple sugar iron medium was taken and the organism was stabbed to the butt as 
well streaked on the surface. It was incubated for 18-24hours at 37
0
C, and then looked 
for the presence of growth and change in pH Growth with no change in PH (slant and 
butt) indicated the organism to be nonfermenting. 
6. CITRATE UTILIZATION TEST  
Sodium citrate is a salt of citric acid seen in metabolism in Krebs cycle. Some 
bacteria utilize citrate as the sole source of carbon and it is detected by the production 
of alkaline by products Christensen’s citrate media was used. The organisms were 
streaked on the surface of the slant and incubated at 37
0
C for 18-24hrs. Development 
of deep blue color of the medium with growth was taken as positive. 
8. UREASE TEST  
Urea is a diamide carbonic acid which when hydrolyzed releases ammonia and 
carbon dioxide. Urease is an enzyme when present hydrolyses urea and release ammonia 
changing the medium to alkaline, PH. 
The organism was streaked on the surface of the slant and incubated at 37
0
C for 
18-24 hours. Development of magenta pink of the medium along with growth was taken 
as positive. 
9. NITRATE REDUCTION TEST  
The capacity of an organism to reduce nitrates to nitrites is shown by this test.  
The  presence  of  nitrate  in  the  medium  is  detected  by addition  of  a naphthalamine 
and sulphanilic acid. 
The organism was inoculated in nitrate broth and incubated at 37
0
C for 18- 24 
hours and observed for gas production by Durham’s tube. One ml each of reagents a 
naphthalamine & sulphanilic acid were added simultaneously and looked for the 
development of red color. Development of red color was taken as positive and when it 
was negative zinc dust was added. When the red color developed after adding zinc the 
test was taken as negative because it indicated the presence of residual nitrates. 
10. GROWTH AT 42
0
C  
The organism was plated in nutrient agar plate and incubated at 42
0
C for 18-24 
hours and looked for growth. Presence of uniform growth indicated positive results. 
11. GROWTH AT 44
0
C  
The organism was plated in nutrient agar plate and incubated at 44
0
C for 
18-24 hours and looked for growth. Presence of uniform growth Indicated positive 
results. 
12. POLYMYXIN B SENSITIVITY  
The organism was plated on nutrient agar plate and a polymyxin B disc of 300U was 
kept. It was incubated at 37
0
C for 18-24 hrs and looked for zone of inhibition 
 
SPECIAL BIOCHEMICAL TESTS USED FOR IDENTIFICATION OF NON 
FERMENTERS 
1. HUGH – LEIFSON OXIDATION - FERMENTATION MEDIUM 
Peptone: 2g 
Sodium Chloride: 5g  
D-Glucose: 10g  
Bromothymol blue: 0.03g  
Agar: 3.0g 
Dipotassium Phosphate: 0.3g 
Distilled water: 1 litre pH: 7% 
 
Medium was sterilized by autoclaving. After cooling the medium to 45
0
C, filter 
sterilized carbohydrate solution was added to get a final concentration of 1% 
Carbohydrates used for the study were glucose, maltose, xylose, fructose and mannitol. 
Of medium was poured as a butt and without a slant into tubes. Two tubes were required 
for the test, each inoculated with the unknown organism, using a straight needle stabbing 
the medium three to four times half way to the bottom of the tube. One tube of each pair 
was covered with a 1cm layer of sterile mineral oil (or) melted paraffin, leaving the 
other open to the air. Both tubes were incubated at 35
0
C and examined daily for several 
days. 
In case of oxidative metabolism, yellow color appears along the upper one fourth 
of the medium and in the tube where no oil overlay was done. In case of fermentative 
organisms yellow color develops in both the tubes. 
 
CONTROL 
Glucose fermentation: Escherichia coli Glucose oxidation: Pseudomonas 
aeruginosa Non saccharolytic: Alcaligenes species. 
 
2. DECARBOXYLATION OF LYSINE, ARGININE & ORNITHINE  
Decarboxylases are a group of specific enzymes which react with carboxyl 
portion of aminoacid forming alkaline reacting amines. The reaction is decarboxylation. 
Each enzyme is specific for Lysine, Arginine and Ornithine. 
INGREDIENTS 
Yeast extract: 5g  
Peptone: 5g  
Glucose: 0.5g  
Pyridoxal: 5mg 
Bromocresol Purple: 5ml  
Cresol Red: 2.5ml  
Distilled water: 1 ltr. 
All aminoacids were added individually to a final concentration of 1% Ph 
adjusted at 6.0 & autoclaved at 15lbs for 15 minutes. 
 
PROCEDURE 
The organism was inoculated in four tubes. One having the basal medium 
without aminoacid for control. Other three tubes having lysine, arginine and ornithine 
each. All tubes were overlaid with liquid paraffin. All were incubated at 37
0
C for 24 
hours. 
The control tube turned yellow indicating that the organism is viable and the test 
medium turning blue purple indicating positive result. 
 
3. O–NITROPHENYL β - D GALACTOPYRANOSIDE  
Reagent 
Sodium Phosphate buffer 1M pH 7.0 – 5ml 
O – Nitrophenyl β - D – galactopyranoside – 80mg 
Distilled water – 15ml. 
A dense suspension of the test organism grown in TSI agar was prepared in 
saline.About 1 drop of toluene was added to the suspension and 0.2ml of ONPG solution 
was added to the suspension and incubated at 37
0C β -galactosidase producing organism 
show yellow color after 1 hour or 18-24 hours incubation. 
 
CONTROL 
Positive Control – Escherichia coli 
Negative control – Proteus species. 
 
4. ACETAMIDE AGAR 
Ingredients 
Magnesium Sulphate: 0.2g 
Ammonium dihydrogen Phosphate: 1g  
Pottasium monohydrogen phosphate: 1g  
Sodium Chloride: 5g 
Acetamide: 10g 
Bromothymol blue solution: 6.4ml 
Agar: 15g 
Final pH: 6.9 
Distilled water: 1 litre 
The ingredients are mixed and pH adjusted to 6.9, dispensed into screw cap tubes 
and sterilized at 121
0
C for 15 min. The medium was allowed to cool in a slant. The 
slant was inoculated with a portion of isolated colony and incubated at 37
0
C overnight 
and was observed for color change. Tubes with negative result were further incubated 
for 7days. 
 
Control 
Positive control: Pseudomonas aeruginosa 
Negative Control: Stenotrophomonas maltophilia 
 
5. GELATIN LIQUEFACTION TEST  
Gelatin breakdown can be demonstrated by incorporating it in a buffered nutrient 
agar, growing the culture and then flooding the medium with mercuric chloride that 
differentially precipitates either gelatin or its breakdown products causing opacity in the 
medium with clear zones around gelatin-liquefying colonies. 
 
CONTROL 
Positive control: Pseudomonas aeruginosa 
Negative Control: Stenotrophomonas maltophilia 
 
PCR Primers and procedure 
Primers used for the polymerase chain reaction for each gene tested includes: 
blaTEM  ATAAAATTCTTGAAGACGAAA; 
GACAGTTACCAATGCTTAATCA        
blaSHV  TCAGCGAAAAACACCTTG; 
TCCCGCAGATAAATCACC 
blaCTX-M  ATGTGCAGYACCAGTAARGTKATGGC; 
TGGGTRAARTARGTSACCAGAAYCAGCG 
bla AmpC    AAC ATG GGG TAT CAG GGA GAT G 
CAA AGC GCG TAA CCG GAT TGG 
blaNDM ; GGTTTGGCGATCTGGTTTC 
CGGAATGGCTCATCACGATC 
BlaVIM  AGT GGT GAG TAT CCG ACA G -3’ 
ATG AAA GTG CGT GGA GAC -3 
 
PCR was conducted with 1μl of boiled bacterial suspensions, 0.5μl of each 
primer, 2μl 5mM of dNTP, 2.μl 10mM Tris-HCL (pH 8.3), 0.75 μl 50mM Mgcl2 
and 2U of Taq DNA polymerase in a total volume of 20μl 
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     ABBREVIATIONS  
 
MDR  - Multidrug resistant  
ESBL - Extended Spectrum of Betalactamases  
MBL  - Metallo betalactamases  
ONPG - O–Nitrophenyl β - D Galactopyranoside  
ATCC - American Type Culture Collection  
CFU  - Colony Forming Units.  
CLED - Cystine Lactose Electrolyte Deficient  
CLSI  - Central Laboratory Standards Institute  
ELISA - Enzyme Linked Immunosorbent Assay  
E- TEST - Epsilometer Test 
DDST - Double Disc Synergy Test  
CDDT - Combined Disc Diffusion Test  
MHA  - Mueller Hinton Agar  
MIC  - Minimum Inhibition Concentration  
PCR  - Polymerase Chain Reaction  
PFGE - Pulsed-Field Gel Electrophoresis  
SPSS  - Statistical Package for Social Science  
IR  - Intrinsically Resistant  
KEY TO MASTER CHART  
 
M - Male patient  
F - Female patient  
UTI - Urinary tract infection  
DM - Diabetes Mellitus  
S - Susceptible  
R - Resistant  
AMP - Ampicillin  
AMX - Amoxicillin  
CTR - Ceftriaxone  
CAZ - Ceftazidime  
AK - Amikacin 
GEN - Gentamicin  
CIP - Ciproflaxacin  
COT - Cotrimoxazole  
PIT - Piperacillin tazobactam  
CX - Cefoxitin  
IMP - Imipenem  
LE - Levofloxacin  
NIT - Nitrofurantoin  
LZ - Linezolid  
VA - Vancomycin 
E - Erythromycin 
CD - Clindamycin 
CL - Colisitin  
ESBL - Extended spectrum betalactamases  
MBL - Metallobetalactamases  
Amp C- AmpC betalactamases 
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4458 46 F 1 NEGATIVE  225 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
4487 48 F 8 POSITIVE DYSURIA 100 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
4599 55 F 5 NEGATIVE  204 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
5132 37 F 1 POSITIVE DYSURIA 220 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
5389 66 M 1 NEGATIVE  230 POSITIVE POSITIVE NEGATIVE POSITIVE POSITIVE E.COLI S S S S S S S S S S S S S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
5443 61 F 10 NEGATIVE  180 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
5456 55 F 5 NEGATIVE  190 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
5455 54 M 15 NEGATIVE  135 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
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OF 
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OF 
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7915 74 M 10 POSITIVE DYSURIA 272 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
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8273 55 F 11 POSITIVE DYSURIA 180 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8293 60 F 15 POSITIVE DYSURIA 195 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8295 75 F 10 POSITIVE DYSURIA 180 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI R S S R R R S R S S S R R R POSITIVE POSITIVE POSITIVE POSITIVE POSITIVE NEGATIVE 
8392 50 M 3 POSITIVE DYSURIA 190 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8381 70 M 15 POSITIVE DYSURIA 150 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8382 47 M 10 POSITIVE 
FREQUENCY 
OF 
URINATION 
169 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8386 47 F 6 POSITIVE DYSURIA 260 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8600 42 F 5 POSITIVE DYSURIA 400 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8611 68 F 10 POSITIVE DYSURIA 220 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
8747 78 F 20 POSITIVE DYSURIA 290 POSITIVE POSITIVE POSITIVE POSITIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S S S R R - S S S S R S R NEGATIVE  NEGATIVE  NEGATIVE  
9090 48 F 20 NEGATIVE  180 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
9110 76 M 10 POSITIVE DYSURIA 153 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
9110 70 M 10 POSITIVE DYSURIA 104 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
9113 65 M 15 POSITIVE DYSURIA 142 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
9845 70 M 6 POSITIVE DYSURIA 165 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE 
PROTEUS 
MIRABILIS 
S S S S R S S S S S S S R S NEGATIVE    NEGATIVE  
9939 53 F 4 NEGATIVE  242 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10470 56 F 8 NEGATIVE  185 NEGATIVE POSITIVE NEGATIVE POSITIVE POSITIVE E.COLI S R S R R S S R S S R S R S POSITIVE POSITIVE POSITIVE POSITIVE NEGATIVE  
10467 30 F 2 NEGATIVE  224 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10526 38 F 3 NEGATIVE  185 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI S S S S S R R S S S S S S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
10592 68 M 7 NEGATIVE  170 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE E.COLI S R S R R R R R S S R S R S POSITIVE POSITIVE POSITIVE POSITIVE NEGATIVE  
10585 52 F 3 POSITIVE DYSURIA 185 NEGATIVE POSITIVE POSITIVE POSITIVE POSITIVE E.COLI S S S S R S S R S S S S R R NEGATIVE NEGATIVE POSITIVE POSITIVE NEGATIVE  
10590 49 F 3 POSITIVE DYSURIA 85 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10599 50 F 1 NEGATIVE  169 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10622 59 F 9 POSITIVE DYSURIA 168 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE 
PROTEUS 
MIRABILIS 
S S S S S S S S S S S S S S NEGATIVE    NEGATIVE  
10623 58 F 9 NEGATIVE  141 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10624 35 F 5 NEGATIVE  160 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10627 45 F 1 POSITIVE 
FREQUENCY 
OF 
URINATION 
110 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10626 44 F 1 POSITIVE DYSURIA 283 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10628 55 F 17 NEGATIVE  100 NEGATIVE POSITIVE POSITIVE POSITIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
R S R R R S - S S S S S R S POSITIVE  NEGATIVE  POSITIVE NEGATIVE 
10629 50 F 6 NEGATIVE  147 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10630 55 F 5 NEGATIVE  113 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10631 59 M 1 NEGATIVE  124 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10632 37 M 2 NEGATIVE  136 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10633 73 F 10 NEGATIVE  232 POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S R R R S - R S S R R R R POSITIVE POSITIVE POSITIVE POSITIVE NEGATIVE  
10634 56 F 7 NEGATIVE  148 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10656 54 F 19 NEGATIVE  143 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI S R S S S R R R S S S S S S POSITIVE NEGATIVE POSITIVE POSITIVE NEGATIVE  
10659 61 M 3 NEGATIVE  160 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10665 45 F 1 NEGATIVE  143 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10677 53 M 13 NEGATIVE  104 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10678 53 F 1 POSITIVE 
FREQUENCY 
OF 
URINATION 
95 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10679 65 F 10 NEGATIVE  170 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10680 65 F 5 POSITIVE 
FREQUENCY 
OF 
URINATION 
156 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10681 65 F 10 NEGATIVE  229 POSITIVE POSITIVE POSITIVE POSITIVE POSITIVE E.COLI S S S S S R S S S S S S S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
10682 58 F 5 NEGATIVE  140 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10683 73 F 11 NEGATIVE  142 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10684 54 F 6 NEGATIVE  135 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10685 65 F 3 POSITIVE DYSURIA 142 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10686 65 F 3 POSITIVE DYSURIA 142 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10688 44 M 10 NEGATIVE  168 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10689 62 F 5 NEGATIVE  180 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10690 52 M 12 POSITIVE DYSURIA 143 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10691 30 M 3 POSITIVE DYSURIA 189 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
16713 52 M 7 POSITIVE DYSURIA 193 NEGATIVE POSITIVE POSITIVE POSITIVE POSITIVE E.COLI S S S R R R S S S S S S S R POSITIVE POSITIVE POSITIVE NEGATIVE NEGATIVE  
16714 61 F 5 NEGATIVE  138 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10704 60 F 1 POSITIVE DYSURIA 119 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE 
PSEUDOMONAS 
AERUGINOSA 
S S R S S - - S S S S S S S NEGATIVE  NEGATIVE  NEGATIVE  
10709 72 F 6 NEGATIVE  170 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10710 75 F 13 NEGATIVE  262 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10721 44 F 5 NEGATIVE  247 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10764 80 M 15 POSITIVE 
FREQUENCY 
OF 
URINATION 
120 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10765 53 M 7 POSITIVE 
FREQUENCY 
OF 
URINATION 
134 NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S S S S S S S R S S S R R NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
10766 62 F 6 POSITIVE DYSURIA 300 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10724 56 M 3 NEGATIVE  292 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10741 58 F 7 NEGATIVE  312 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10729 40 M 2 NEGATIVE  242 POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NG                     
10736 56 F 10 NEGATIVE  208 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10792 40 M 6 NEGATIVE  278 POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10793 52 F 5 NEGATIVE  283 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10794 38 F 5 NEGATIVE  298 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10795 65 F 7 NEGATIVE  135 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10796 65 F 8 POSITIVE DYSURIA 153 NEGATIVE POSITIVE POSITIVE NEGATIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S S S S S - S S S S R R S NEGATIVE  NEGATIVE  NEGATIVE  
10797 30 F 6 POSITIVE DYSURIA 202 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10798 61 F 20 NEGATIVE  280 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10802 68 F 16 NEGATIVE  163 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10803 70 M 10 POSITIVE DYSURIA 140 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10804 58 F 7 NEGATIVE  148 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10805 57 F 17 NEGATIVE  165 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10806 55 F 15 POSITIVE DYSURIA 156 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10807 58 F 15 POSITIVE DYSURIA 425 POSITIVE POSITIVE NEGATIVE POSITIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S R R S S - S S S R S R S NEGATIVE  NEGATIVE  NEGATIVE  
10808 53 F 4 NEGATIVE  162 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
10809 55 F 13 NEGATIVE  180 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11089 43 F 6 NEGATIVE  117 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11090 42 F 5 NEGATIVE  145 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11091 64 F 8 NEGATIVE  250 POSITIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI S S R R R S S S S S R R R S POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
11092 44 F 10 NEGATIVE  263 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11094 60 F 12 NEGATIVE  161 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11079 53 F 8 NEGATIVE  164 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NG                     
11062 60 F 10 NEGATIVE  135 NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11063 55 F 9 NEGATIVE  282 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11064 63 M 30 NEGATIVE  308 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE 
KLEBSIELLA 
PNEUMONIAE 
S S S S S R - S S S S R S S NEGATIVE  NEGATIVE  NEGATIVE  
11065 62 F 10 POSITIVE DYSURIA 250 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11068 45 F 7 NEGATIVE  163 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11069 58 F 8 NEGATIVE  142 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11070 59 M 8 NEGATIVE  142 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11319 45 F 5 NEGATIVE  180 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11320 55 F 8 POSITIVE DYSURIA 137 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11321 65 F 10 POSITIVE DYSURIA 240 NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE E.COLI S S S R R S R S S S R S R R POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
11322 50 F 5 NEGATIVE  159 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11323 48 M 8 NEGATIVE  157 NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11324 58 F 3 POSITIVE DYSURIA 182 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11325 71 F 4 NEGATIVE  203 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11301 38 F 5 NEGATIVE  230 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11343 68 F 10 NEGATIVE  308 POSITIVE NEGATIVE NEGATIVE POSITIVE POSITIVE E.COLI S S S R R S R S S S S S S S POSITIVE POSITIVE POSITIVE NEGATIVE NEGATIVE  
11370 40 F 8 NEGATIVE  126 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11371 42 F 7 NEGATIVE  176 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11373 52 F 6 NEGATIVE  124 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11375 50 F 5 POSITIVE DYSURIA 81 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11400 50 F 5 POSITIVE DYSURIA 284 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11402 52 F 10 NEGATIVE  140 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE E.COLI S R R R R R R R S S S R S S POSITIVE POSITIVE POSITIVE POSITIVE NEGATIVE  
11403 58 F 5 NEGATIVE  203 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11406 60 F 10 NEGATIVE  102 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11407 60 F 16 NEGATIVE  218 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11408 65 F 3 NEGATIVE  108 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11409 57 F 4 NEGATIVE  95 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE E.COLI S R S R R R R R S S R R R S POSITIVE POSITIVE POSITIVE POSITIVE NEGATIVE  
11622 46 F 5 POSITIVE 
DYSURIA,FR
EQUENCY OF 
URINATION 
92 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
11623 60 F 7 POSITIVE 
FREQUENCY 
OF 
URINATION, 
SUPRAPUBIC 
PAIN , 
FEVER 
169 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
389 52 F 10 POSITIVE 
FREQUENCY 
OF 
URINATION, 
SUPRAPUBIC 
PAIN ,FEVER 
120 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
390 46 M 5 NEGATIVE  273 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
391 80 F 15 POSITIVE DYSURIA 157 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
392 50 F 9 POSITIVE DYSURIA 94 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
393 40 F 10 NEGATIVE  182 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
394 52 F 10 NEGATIVE  214 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
396 60 F 8 POSITIVE DYSURIA 191 NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE E.COLI S S S R R R R S S S S R R S POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
397 55 F 10 NEGATIVE  165 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
398 40 F 7 NEGATIVE  192 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
399 68 F 4 NEGATIVE  170 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S S S S R R S S S R R S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
400 58 F 7 NEGATIVE  216 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
497 67 F 6 NEGATIVE  160 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
498 50 F 4 NEGATIVE  185 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
499 50 M 6 NEGATIVE  115 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
500 70 F 10 NEGATIVE  220 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
501 47 F 7 POSITIVE DYSURIA 168 NEGATIVE POSITIVE POSITIVE POSITIVE NEGATIVE NG                     
502 42 F 5 POSITIVE 
FREQUENCY 
OF 
URINATION 
262 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
504 70 F 7 POSITIVE DYSURIA 156 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
503 70 F 8 POSITIVE DYSURIA 221 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
505 50 F 3 NEGATIVE  144 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
506 48 F 4 NEGATIVE  257 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
507 50 F 7 NEGATIVE  121 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
508 45 M 1 NEGATIVE  86 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
509 55 F 6 NEGATIVE  125 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
511 35 F 7 POSITIVE 
FREQUENCY 
OF 
URINATION 
164 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
512 40 M 8 NEGATIVE  182 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
513 55 F 6 POSITIVE FEVER 174 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
856 37 F 5 NEGATIVE  193 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
857 52 F 15 NEGATIVE  178 NEGATIVE POSITIVE POSITIVE POSITIVE POSITIVE E.COLI S S R R R S S S S S S S S R POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
858 55 F 7 POSITIVE 
FREQUENCY 
OF 
URINATION,F
EVER 
219 POSITIVE NEGATIVE POSITIVE POSITIVE NEGATIVE NG                     
859 61 F 8 POSITIVE DYSURIA 219 POSITIVE POSITIVE NEGATIVE NEGATIVE POSITIVE NG                     
861 48 F 6 POSITIVE DYSURIA 301 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG        S S S S S         
870 45 F 6 POSITIVE DYSURIA 265 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
862 60 F 7 NEGATIVE  151 NEGATIVE POSITIVE NEGATIVE POSITIVE POSITIVE E.COLI S S R R R R S S S S S S S S POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
863 42 F 5 NEGATIVE  162 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
882 46 M 6 NEGATIVE  118 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
883 44 M 7 POSITIVE DYSURIA 145 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
884 47 F 8 POSITIVE DYSURIA 167 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
886 31 F 2 POSITIVE DYSURIA 143 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
887 34 M 2 POSITIVE DYSURIA 114 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1738 60 F 12 POSITIVE 
DYSURIA,FR
EQUENCY OF 
URINATION,F
EVER 
198 POSITIVE NEGATIVE NEGATIVE POSITIVE POSITIVE NG                     
1739 63 F 17 POSITIVE 
FREQUENCY 
OF 
URINATION, 
SUPRAPUBIC 
PAIN ,FEVER 
175 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1740 49 M 5 POSITIVE 
FREQUENCY 
OF 
URINATION 
146 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1741 63 M 10 POSITIVE 
FREQUENCY 
OF 
URINATION 
197 POSITIVE NEGATIVE NEGATIVE POSITIVE POSITIVE E.COLI R S R R R R R S S S S S S R POSITIVE POSITIVE POSITIVE NEGATIVE POSITIVE POSITIVE 
1698 45 F 15 POSITIVE ITCHING 156 NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE E.COLI S S S R R S R S S S S R R R POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
1703 52 F 5 POSITIVE DYSURIA 188 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1736 34 F 1 POSITIVE DYSURIA 125 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE 
PSEUDOMONAS 
AERUGINOSA 
R S S S - - - S S S R S S R NEGATIVE  NEGATIVE  POSITIVE POSITIVE 
1747 67 F 10 POSITIVE ITCHING 144 NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE E.COLI S S R S S R S S S R S S R R NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
1763 70 M 15 POSITIVE 
FREQUENCY 
OF 
URINATION 
158 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE E.COLI S S S S S R R S S S S R R R NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
1803 62 M 8 POSITIVE 
FREQUENCY 
OF 
URINATION 
165 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE E.COLI R S R R R R R S S S S R R S POSITIVE POSITIVE NEGATIVE NEGATIVE POSITIVE POSITIVE 
1804 53 F 5 POSITIVE DYSURIA 132 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1805 72 F 12 POSITIVE DYSURIA 245 POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE 
ACINETOBACTER 
SP. 
S S S S S R S S S S S S S R NEGATIVE  NEGATIVE  NEGATIVE  
1777 71 M 5 POSITIVE DYSURIA 234 POSITIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE E.COLI S S R S S R R S S R S R R S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
1810 56 M 6 POSITIVE 
FREQUENCY 
OF 
URINATION 
109 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1811 65 F 12 NEGATIVE  131 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1815 64 M 10 NEGATIVE  117 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1831 50 F 5 NEGATIVE  156 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE E.COLI R S S S S S R S S S S R S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE 
1844 50 F 5 NEGATIVE  156 NEGATIVE NEGATIVE POSITIVE NEGATIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S S R R R - S S S S S S S NEGATIVE  POSITIVE NEGATIVE NEGATIVE  
1847 45 M 3 NEGATIVE  112 NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE 
PSEUDOMONAS 
AERUGINOSA 
S S S - - - - S S S R S S S NEGATIVE  NEGATIVE  NEGATIVE  
1874 58 M 10 NEGATIVE  165 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1876 78 M 7 POSITIVE 
FREQUENCY 
OF 
URINATION, 
SUPRAPUBIC 
PAIN ,FEVER 
123 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1885 30 F 2 POSITIVE DYSURIA 145 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE NG                     
1867 29 F 2 POSITIVE DYSURIA 152 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE 
KLEBSIELLA 
PNEUMONIAE 
S S R S R R - S S S S R S S NEGATIVE  NEGATIVE  NEGATIVE  
1973 32 F 3 POSITIVE DYSURIA 179 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI S S S R R R S R S S S R R R POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
1974 51 M 5 POSITIVE 
FREQUENCY 
OF 
URINATION 
222 POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1975 68 F 8 POSITIVE 
FEVER,SUPR
APUBIC 
194 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
PAIN,ITCHIN
G 
1975 45 F 3 POSITIVE DYSURIA 165 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI S S R S S S S S S S S S R R NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
1914 40 M 1 POSITIVE ITCHING 123 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1923 52 F 4 POSITIVE ITCHING 146 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S R S S S S S S S S S S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE 
2016 41 F 1 POSITIVE DYSURIA 112 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1944 63 M 10 POSITIVE DYSURIA 166 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NG                     
1944 38 F 2 POSITIVE 
FREQUENCY 
OF 
URINATION,F
EVER 
132 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S R S S S S S S S S S S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE 
1964 55 F 5 POSITIVE 
FREQUENCY 
OF 
URINATION 
165 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1967 72 M 12 POSITIVE ITCHING 223 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1968 42 F 2 POSITIVE DYSURIA 113 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
1980 50 F 7 POSITIVE DYSURIA 101 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE E.COLI S S R S S S S S S S S S R S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
2012 42 F 5 POSITIVE 
FREQUENCY 
OF 
URINATION,F
EVER 
139 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2026 46 F 7 POSITIVE DYSURIA 143 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI S S S S S S R S S R S R R R NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
2040 48 F 7 POSITIVE DYSURIA 156 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S S R S S - S S R S R S R NEGATIVE  NEGATIVE  NEGATIVE  
2054 48 F 7 POSITIVE DYSURIA 156 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE E.COLI S S R R R R S S S R S R R S POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
2060 55 F 6 POSITIVE DYSURIA 122 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S S S S S S S S S S S S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE  
2198 60 F 8 POSITIVE 
FREQUENCY 
OF 
URINATION,F
EVER 
187 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE NG                     
2199 65 F 10 POSITIVE ITCHING 243 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2176 52 F 5 POSITIVE ITCHING 125 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S R S S S S S S S S S S S NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE 
2177 56 F 3 POSITIVE DYSURIA 120 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2179 72 M 15 POSITIVE 
FREQUENCY 
OF 
URINATION, 
SUPRAPUBIC 
PAIN ,FEVER 
165 NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE 
ACINETOBACTER 
SP. 
R R S S S R R S S S S S S R NEGATIVE  NEGATIVE  NEGATIVE  
2180 72 F 16 POSITIVE DYSURIA 189 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S S R R S S S S S S R R R POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
2190 40 M 3 NEGATIVE  134 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2191 44 F 1 NEGATIVE  110 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2192 67 M 15 NEGATIVE  176 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2193 56 F 4 NEGATIVE  113 NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE E.COLI S S S R R S S S S S S S S S POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
2194 50 F 2 NEGATIVE  156 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2195 74 F 15 NEGATIVE  246 NEGATIVE NEGATIVE POSITIVE NEGATIVE POSITIVE E.COLI S S S R R R R S S R S R R S POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
2175 46 F 3 NEGATIVE  134 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
2288 45 F 5 NEGATIVE  128 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3628 55 F 3 NEGATIVE  197 POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3629 61 F 10 NEGATIVE  165 NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3630 55 F 3 NEGATIVE  110 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3631 48 F 8 NEGATIVE  139 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3632 64 F 10 NEGATIVE  132 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3633 35 F 1 NEGATIVE  126 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3634 45 F 4 POSITIVE DYSURIA 214 POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE E.COLI S S R R R R R S S S S S S R POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE  
3635 40 F 2 NEGATIVE  113 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG                     
3636 53 F 5 POSITIVE DYSURIA 179 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S S S S R - S S S S R S S NEGATIVE  NEGATIVE  NEGATIVE  
3637 53 F 5 POSITIVE DYSURIA 179 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE 
KLEBSIELLA 
PNEUMONIAE 
S S R S S R - S S S S S S S NEGATIVE  NEGATIVE  NEGATIVE  
3638 62 M 10 NEGATIVE  71 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NG        S S S           
 
 
 LAB NO: AGE SEX DURATION OF DM UTI SYMPTOMS SYMPTOMS FBS GLUCOSE PUS CELL NITRITE REDUCTASE LEUKOCYTE ESTERASE DGS ORGANISM P AMC AMP CX AK GEN CIPRO NX NIT COT CD VA 
4865 52 F 6 NEGATIVE  300 NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE S.AUREUS S S - S S S S S R S S S 
4578 54 F 15 NEGATIVE  250 POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE S.AUREUS S S - S S S S S S S S S 
5565 50 F 5 POSITIVE DYSURIA,FREQUENCY OF URINATION 125 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE S.AUREUS S S - S S S S R R S S S 
6789 61 M 7 NEGATIVE  211 POSITIVE POSITIVE NEGATIVE NEGATIVE POSITIVE ENTEROCOCCUS FAECALIS S - S - S S S S S - S S 
6720 50 F 3 NEGATIVE  232 POSITIVE POSITIVE NEGATIVE NEGATIVE POSITIVE S.AUREUS R S - S S S R S S R S S 
8296 75 F 10 POSITIVE DYSURIA 180 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE ENTEROCOCCUS FAECALIS S - R - S S S S S - S S 
8758 78 F 20 POSITIVE DYSURIA 290 POSITIVE POSITIVE POSITIVE POSITIVE POSITIVE ENTEROCOCCUS FAECALIS S - R - R S R S S - S S 
9385 48 M 10 POSITIVE DYSURIA 185 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE S.AUREUS S S - S S S S S R S S S 
10625 65 F 9 POSITIVE DYSURIA 300 POSITIVE POSITIVE NEGATIVE NEGATIVE POSITIVE CONS S R - S S S R S S S S S 
10687 68 F 11 POSITIVE FREQUENCY OF URINATION 188 NEGATIVE POSITIVE NEGATIVE POSITIVE POSITIVE S.AUREUS R R - S S S S S S S S S 
10762 74 M 10 NEGATIVE  324 POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE ENTEROCOCCUS FAECALIS S - S - S S S R S - S S 
10749 75 F 5 NEGATIVE  284 POSITIVE POSITIVE NEGATIVE POSITIVE POSITIVE S.AUREUS R R - S S S R S S S S S 
11093 55 F 15 NEGATIVE  143 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE ENTEROCOCCUS FAECALIS S - S - S S S S S - S S 
11066 58 M 11 NEGATIVE  142 NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE ENTEROCOCCUS FAECALIS R - R - S S S S S - R S 
11067 50 F 10 NEGATIVE  111 NEGATIVE POSITIVE NEGATIVE POSITIVE POSITIVE S.AUREUS R R - S S S S S S R S S 
11326 52 F 5 NEGATIVE  140 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE CONS S S - S S S S R S S S S 
11372 48 F 5 NEGATIVE  136 NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE CONS S S - S S S S S S S S S 
11374 52 M 10 POSITIVE DYSURIA 154 NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE S.AUREUS R S - S S S R S S R R S 
11401 49 F 15 NEGATIVE  229 POSITIVE POSITIVE NEGATIVE NEGATIVE POSITIVE S.AUREUS R R - S S S R S S S S S 
11404 62 F 15 NEGATIVE  182 NEGATIVE POSITIVE POSITIVE NEGATIVE POSITIVE ENTEROCOCCUS FAECALIS R - S - S S S S R - S S 
11405 45 F 15 NEGATIVE  384 POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE S.AUREUS S S - S S S R S R S R S 
388 52 F 4 NEGATIVE  190 POSITIVE POSITIVE POSITIVE POSITIVE POSITIVE S.AUREUS S S - S S S R R R R S S 
395 55 F 7 NEGATIVE  272 POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE ENTEROCOCCUS FAECALIS S - R - S S S S R - R S 
510 50 M 8 NEGATIVE  155 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE S.AUREUS S S - S S S S S S R S S 
860 61 M 10 POSITIVE DYSURIA 105 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE S.AUREUS S S - S S S R S S R R S 
868 48 F 10 POSITIVE SUPRAPUBIC PAIN,FEVER 120 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE S.AUREUS R R - R S R R S S S S S 
869 46 F 7 POSITIVE FREQUENCY OF URINATION,SUPRAPUBIC PAIN ,FEVER 139 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE S.AUREUS S R - R S S R S S S S S 
885 60 F 10 POSITIVE FREQUENCY OF URINATION,FEVER 178 NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE ENTEROCOCCUS FAECALIS S - S - S S S R S - S S 
1075 60 F 10 POSITIVE DYSURIA 166 NEGATIVE POSITIVE POSITIVE POSITIVE POSITIVE ENTEROCOCCUS FAECALIS R - S - S R R S S - R S 
1742 60 F 7 NEGATIVE  167 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE ENTEROCOCCUS FAECALIS R - S - S S S S S - R S 
1728 50 F 10 POSITIVE DYSURIA 145 NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE S.AUREUS S R - S S S R S S R R S 
1804 60 F 8 POSITIVE FREQUENCY OF URINATION 179 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE S.AUREUS R S - S S S S S S S S S 
1762 32 F 2 POSITIVE FREQUENCY OF URINATION,SUPRAPIBIC PAIN ,FEVER 232 POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE CONS S S - S S S R S S S S S 
2009 40 F 2 POSITIVE DYSURIA 275 POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE S.AUREUS S S - R S S S S S S S S 
2019 48 F 9 POSITIVE FREQUENCY OF URINATION 218 POSITIVE NEGATIVE POSITIVE POSITIVE POSITIVE S.AUREUS S R - R S S S S S S R S 
2178 62 F 10 POSITIVE DYSURIA 242 POSITIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE ENTEROCOCCUS FAECALIS R - S - S R R S S - S S 
2180 56 F 7 NEGATIVE  146 NEGATIVE NEGATIVE POSITIVE POSITIVE POSITIVE ENTEROCOCCUS FAECALIS S - R - S S S R S - S S 
 
